WO2023107965A1 - Formes salines et solides du 1-(2,5-diméthoxy-4-méthylphényl)-2-aminopropane (dom), de la 2,5-diméthoxy-4-iodoamphétamine (doi), de la 2,5-diméthoxy-4-bromoamphétamine (dob) et de la 2,5-diméthoxy-4-chloramphétamine (doc) - Google Patents

Formes salines et solides du 1-(2,5-diméthoxy-4-méthylphényl)-2-aminopropane (dom), de la 2,5-diméthoxy-4-iodoamphétamine (doi), de la 2,5-diméthoxy-4-bromoamphétamine (dob) et de la 2,5-diméthoxy-4-chloramphétamine (doc) Download PDF

Info

Publication number
WO2023107965A1
WO2023107965A1 PCT/US2022/081040 US2022081040W WO2023107965A1 WO 2023107965 A1 WO2023107965 A1 WO 2023107965A1 US 2022081040 W US2022081040 W US 2022081040W WO 2023107965 A1 WO2023107965 A1 WO 2023107965A1
Authority
WO
WIPO (PCT)
Prior art keywords
dom
compound
solid form
radiation
crystalline polymorph
Prior art date
Application number
PCT/US2022/081040
Other languages
English (en)
Inventor
Matthew Duncton
Samuel CLARK
Original Assignee
Terran Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terran Biosciences, Inc. filed Critical Terran Biosciences, Inc.
Publication of WO2023107965A1 publication Critical patent/WO2023107965A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the solid form of DOM, DOI, DOB, or DOC is a salt, and maybe a polymorph of the salt.
  • the salt may be formed from an acid selected from hydrochloric acid, fumaric acid, galactaric (mucic) acid, naphthalene-1,5-disulfonic acid, citric acid, sulfuric acid, d-glucuronic acid, ethane-1,2- disulfonic acid, lactobionic acid, p-toluenesulfonic acid, D-glucoheptonic acid, thiocyanic acid, (-)-L-pyroglutamic acid, methanesulfonic acid, L-malic acid, dodecylsulfuric acid, hippuric acid, naphthalene-2-sulfonic acid, D-gluconic acid, benzenesulfonic acid, D,L-lactic acid, oxalic acid, oleic acid, glycerophosphoric acid, succ
  • a stoichiometric ratio of acid to DOM, DOI, DOB, or DOC is from about 0.4 to about 2.2, such as from about 0.5 to about 2, or from about 0.5, 1 or 2.
  • the solid form may be a crystalline solid, a hydrate, or a combination thereof.
  • the crystalline solid may be substantially a single form, such as a polymorph form.
  • the polymorph may be selected to have one or more desired properties, particularly improved properties, such as physical properties, chemical properties, pharmacokinetic properties, or a combination thereof.
  • the one or more desired properties may comprise melting point, glass transition temperature, flowability, thermal stability, mechanical stability, shelf life, stability against polymorphic transition, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles, bioavailability, absorption, distribution, metabolism, excretion, toxicity including cytotoxicity, dissolution rate, half-life, or a combination thereof.
  • a pharmaceutical composition comprising a solid form of a disclosed compound, and a pharmaceutically acceptable excipient.
  • a method for administering the solid form of DOM, DOI, DOB, or DOC also is disclosed herein.
  • the method comprises administering to a subject an effective amount of a solid form of DOM, DOI, DOB, or DOC, or a pharmaceutical composition thereof.
  • the subject is suffering from a neurological disease or a psychiatric disorder, or both, such as a neurodegenerative disorder.
  • the neurological disorder or psychiatric disorder, or both may comprise depression, addiction, anxiety, or a post-traumatic stress disorder, and/or the neurological disorder or psychiatric disorder, or both, may comprise treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder.
  • the neurological disorder or psychiatric disorder, or both comprises stroke, traumatic brain injury, or a combination thereof.
  • the method may comprise further comprising administering an effective amount of an empathogenic agent and/or a 5-HT 2A antagonist to the subject.
  • the 5-HT 2A antagonist may be selected from MDL-11,939, eplivanserin (SR-46,349), ketanserin, ritanserin, altanserin, acepromazine, mianserin, mirtazapine, quetiapine, SB204741, SB206553, SB242084, LY272015, SB243213, blonanserin, SB200646, RS102221, nefazodone, MDL-100,907, pimavanserin, nelotanserin and lorcaserin.
  • administering the solid form of the compound comprises oral, parenteral, or topical administration.
  • oral administration is used, but in other particular embodiments, administration is by injection, inhalation, intraocular, intravaginal, intrarectal or transdermal routes.
  • FIG. 3 provides an XRPD diffractogram of DOM benzenesulfonate (besylate) salt.
  • FIG. 4 provides an XRPD diffractogram of DOM fumarate salt Form 1.
  • FIG.5 provides an XRPD diffractogram of DOM gentisate salt.
  • FIG. 6 provides an XRPD diffractogram of DOM glutamate salt.
  • FIG. 7 provides an XRPD diffractogram of DOM glutarate salt Form 1.
  • FIG. 8 provides an XRPD diffractogram of DOM glycolate salt Form 1.
  • FIG. 9 provides an XRPD diffractogram of DOM hydrochloride salt.
  • FIG.10 provides an XRPD diffractogram of DOM 1-hydroxy-2-napthoate (xinafoate) salt.
  • FIG. 11 provides an XRPD diffractogram of DOM L-malate salt Form 1.
  • FIG. 12 provides an XRPD diffractogram of a mixture of DOM maleate salt Forms 1 and 2.
  • FIG. 13 provides an XRPD diffractogram of DOM malonate salt Form 1.
  • FIG. 14 provides an XRPD diffractogram of DOM mesylate salt.
  • FIG. 15 provides an XRPD diffractogram of a mixture of DOM mucate salt and mucic acid.
  • FIG. 16 provides an XRPD diffractogram of DOM phosphate salt.
  • FIG. 11 provides an XRPD diffractogram of DOM 1-hydroxy-2-napthoate (xinafoate) salt.
  • FIG. 11 provides an XRPD diffractogram of DOM L-malate salt Form 1.
  • FIG. 17 provides an XRPD diffractogram of DOM sulfate salt.
  • FIG. 18 provides an XRPD diffractogram of DOM succinate salt.
  • FIG. 19 provides an XRPD diffractogram of DOM L-tartrate salt Form 1.
  • FIG. 20 provides an XRPD diffractogram of DOM tosylate salt Form 1.
  • FIG. 21 provides an XRPD diffractogram of DOM mucate salt.
  • FIG. 22 provides an XRPD diffractogram of DOM ethanesulfonate (esylate) salt.
  • FIG. 23 provides an XRPD diffractogram of DOM lactate salt.
  • FIG.24 provides a 1 H NMR spectrum for DOM adipate.
  • FIG.25 provides TGA and DSC profiles for DOM adipate.
  • FIG.26 provides a 1 H NMR spectrum for DOM benzenesulfonate.
  • FIG. 27 provides TGA and DSC profiles for DOM benzenesulfonate.
  • FIG.28 provides a 1 H NMR spectrum for DOM ethanesulfonate (esylate).
  • FIG. 29 provides TGA and DSC profiles for DOM ethanesulfonate (esylate).
  • FIG.30 provides a 1 H NMR spectrum for DOM glutamate.
  • FIG.31 provides TGA and DSC profiles for DOM glutamate.
  • FIG.32 provides a 1 H NMR spectrum for DOM glutarate Form 1.
  • FIG.33 provides TGA and DSC profiles for DOM glutarate Form 1.
  • FIG.34 provides a 1 H NMR spectrum for DOM glutarate Form 2.
  • FIG.35 provides TGA and DSC profiles for DOM glutarate Form 2.
  • FIG.36 provides a 1 H NMR spectrum for DOM glycolate Form 1.
  • FIG.37 provides TGA and DSC profiles for DOM glycolate Form 1.
  • FIG.38 provides a 1 H NMR spectrum for DOM hydrochloride.
  • FIG. 39 provides TGA and DSC profiles for DOM hydrochloride.
  • FIG.40 provides a 1 H NMR spectrum for DOM lactate.
  • FIG.41 provides TGA and DSC profiles for DOM lactate.
  • FIG.42 provides a 1 H NMR spectrum for DOM L-malate Form 1.
  • FIG.40 provides a 1 H NMR spectrum for DOM lactate.
  • FIG. 43 provides TGA and DSC profiles for DOM L-malate Form 1.
  • FIG.44 provides a 1 H NMR spectrum for DOM maleate Form 1.
  • FIG.45 provides TGA and DSC profiles for DOM maleate Form 1.
  • FIG.46 provides a 1 H NMR spectrum for DOM malonate Form 1.
  • FIG. 47 provides TGA and DSC profiles for DOM malonate Form 1.
  • FIG.48 provides a 1 H NMR spectrum for DOM mucate.
  • FIG.49 provides TGA and DSC profiles for DOM mucate.
  • FIG.50 provides a 1 H NMR spectrum for DOM phosphate.
  • FIG.51 provides TGA and DSC profiles for DOM phosphate.
  • FIG.52 provides a 1 H NMR spectrum for DOM succinate.
  • FIG.53 provides TGA and DSC profiles for DOM succinate.
  • FIG.54 provides a 1 H NMR spectrum for DOM sulfate.
  • FIG.55 provides TGA and DSC profiles for DOM sulfate.
  • FIG.56 provides a 1 H NMR spectrum for DOM L-tartrate Form 1.
  • FIG. 57 provides TGA and DSC profiles for DOM L-tartrate Form 1.
  • FIG.58 provides a 1 H NMR spectrum for DOM tosylate Form 1.
  • FIG.59 provides TGA and DSC profiles for DOM tosylate Form 1.
  • FIG.60 provides a 1 H NMR spectrum for DOM 1-hydroxy-2-naphthoate (xinafoate).
  • FIG.61 provides TGA and DSC profiles for DOM 1-hydroxy-2-naphthoate (xinafoate).
  • FIG.61 provides TGA and DSC profiles for DOM 1-hydroxy-2-naphthoate (xinafoate).
  • FIG.61 provides TGA and DSC profiles for DOM 1-hydroxy-2-na
  • FIG. 62 provides an XRPD diffractogram of DOM benzenesulfonate.
  • FIG. 63 provides an XRPD diffractogram of DOM fumarate Form 2.
  • FIG. 64 provides an XRPD diffractogram of DOM glutarate Form 2.
  • FIG. 65 provides an XRPD diffractogram of DOM maleate Form 1.
  • FIG. 66 provides an XRPD diffractogram of DOM malonate Form 1.
  • FIG. 67 provides an XRPD diffractogram of DOM malonate Form 2.
  • FIG. 68 provides an XRPD diffractogram of DOM phosphate.
  • FIG. 69 provides an XRPD diffractogram of DOM sulfate.
  • FIG. 63 provides an XRPD diffractogram of DOM fumarate Form 2.
  • FIG. 64 provides an XRPD diffractogram of DOM glutarate Form 2.
  • FIG. 65 provides an XRPD diffractogram
  • FIG. 70 provides an XRPD diffractogram of DOM L-tartrate Form 1.
  • FIG. 71 provides an XRPD diffractogram of DOM tosylate Form 2.
  • FIG. 72 provides an XRPD diffractogram of DOM Form A.
  • FIG.73 provides an XRPD diffractogram of DOM Form A post-DVS analysis.
  • FIG.74 provides a 1 NMR spectrum for DOM Form A.
  • FIG.75 provides TGA and DSC profiles for DOM Form A.
  • FIG.76 provides an FT-IR spectrum for DOM Form A.
  • FIG. 77 provides an XRPD diffractogram of a mixture of DOM L-malate Forms 1 and 2.
  • FIG. 78 provides an XRPD diffractogram of DOM L-malate Form 3.
  • FIG. 71 provides an XRPD diffractogram of DOM tosylate Form 2.
  • FIG. 72 provides an XRPD diffractogram of DOM Form A
  • FIG. 79 provides an XRPD diffractogram of DOI HCl.
  • FIG. 80 provides an overlay of XRPD diffractograms of DOM L-malate Form 3 (top), DOM L-malate Forms 1 and 2 (middle), and DOM L-malate Form 1 (bottom).
  • FIG.81 provides the DSC profile of the first heating cycle of DOM L-malate Form 1.
  • FIG.82 provides the DSC profile of the second heating cycle of DOM L-malate Form 1.
  • FIG.83 provides the DSC profile of the third heating cycle of DOM L-malate Form 1.
  • FIG. 84 provides the modulated DSC profile of the non-crystalline L-malate salt.
  • FIG.85 provides the DVS isotherm of DOM glycolate Form 1.
  • FIG. 86 provides the DVS isotherm of DOM L-malate Form 1.
  • FIG.87 provides the DVS isotherm of DOM hydrochloride.
  • the singular forms “a,” “an,” and “the” refer to one or more than one, unless the context clearly dictates otherwise.
  • the term “or” refers to a single element of stated alternative elements or a combination of two or more elements, unless the context clearly indicates otherwise.
  • “comprises” means “includes.” Thus, “comprising A or B,” means “including A, B, or A and B,” without excluding additional elements.
  • administering refers to any suitable mode of administration, including, oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.
  • a slow-release device e.g., a mini-osmotic pump
  • DOM refers to the compound 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane.
  • the compound may also be referred to as 1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine, 2,5-dimethoxy-4-methylamphetamine, or 2,5-DOM.
  • DOI refers to the compound 2,5-dimethoxy-4-iodoamphetamine.
  • the compound may also be referred to as 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine, 2-(4-iodo-2,5- dimethoxyphenyl)-1-methylethylamine, or 4-DOI.
  • DOB refers to the compound 2,5-dimethoxy-4-bromoamphetamine.
  • the compound may also be referred to as 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine, 4-bromo-2,5- dimethoxyamphetamine, or 4-Bromo-DMA.
  • DOB “DOC” refers to the compound 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine.
  • the compound may also be referred to as 2,5-dimethoxy-4-chloroamphetamine.
  • Subject refers to an animal, such as a mammal, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human subject. “Therapeutically effective amount” or “therapeutically sufficient amount” or “effective or sufficient amount” refers to a dose that produces therapeutic effects for which it is administered.
  • the exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols.1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
  • the therapeutically effective dose can often be lower than the conventional therapeutically effective dose for non-sensitized cells.
  • Neurovascular plasticity refers to the ability of the brain to change its structure and/or function continuously throughout a subject’s life.
  • Brain disorder refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post- traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.
  • “Combination therapy” refers to a method of treating a disease or disorder, wherein two or more different pharmaceutical agents are administered in overlapping regimens so that the subject is simultaneously exposed to both agents.
  • the compounds of the present disclosure can be used in combination with other pharmaceutically active compounds.
  • the compounds of the disclosure can be administered simultaneously (as a single preparation or separate preparation) or sequentially to the other drug therapy.
  • a combination therapy envisions administration of two or more drugs during a single cycle or course of therapy.
  • Neurotrophic factors refers to a family of soluble peptides or proteins which support the survival, growth, and differentiation of developing and mature neurons.
  • Modulate or “modulating” or “modulation” refers to an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule.
  • agonists, partial agonists, antagonists, and allosteric modulators e.g., a positive allosteric modulator
  • G protein-coupled receptor e.g., 5HT 2A
  • Agonism refers to the activation of a receptor or enzyme by a modulator, or agonist, to produce a biological response.
  • Ant refers to a modulator that binds to a receptor or enzyme and activates the receptor to produce a biological response.
  • 5HT 2A agonist can be used to refer to a compound that exhibits an EC50 with respect to 5HT 2A activity of no more than about 100 mM.
  • the term “agonist” includes full agonists or partial agonists.
  • Full agonist refers to a modulator that binds to and activates a receptor with the maximum response that an agonist can elicit at the receptor.
  • Partial agonist refers to a modulator that binds to and activates a given receptor, but has partial efficacy, that is, less than the maximal response, at the receptor relative to a full agonist.
  • “Positive allosteric modulator” refers to a modulator that binds to a site distinct from the orthosteric binding site and enhances or amplifies the effect of an agonist. “Antagonism” refers to the inactivation of a receptor or enzyme by a modulator, or antagonist. Antagonism of a receptor, for example, is when a molecule binds to the receptor and does not allow activity to occur. “Antagonist” or “neutral antagonist” refers to a modulator that binds to a receptor or enzyme and blocks a biological response. An antagonist has no activity in the absence of an agonist or inverse agonist but can block the activity of either, causing no change in the biological response.
  • composition refers to a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation.
  • “Pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject.
  • Pharmaceutical excipients useful in the present disclosure include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors.
  • binders fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors.
  • Solid forms of DOM, DOI, DOB, and DOC that are useful to treat various disorders, such as brain disorders. Also disclosed are methods for making the solid forms of DOM, DOI, DOB, or DOC and method of administering the solid forms of DOM, DOI, DOB, or DOC.
  • the solid form of the compound is a crystalline form of DOM, DOI, DOB, or DOC.
  • the solid form of the compound is a salt of the compound.
  • the solid form of DOM is a polymorph of DOM, such as a polymorph of the free base compound or a polymorph of the salt.
  • the solid form of DOI is a polymorph of DOI, such as a polymorph of the free base compound or a polymorph of the salt.
  • the solid form of DOB is a polymorph of DOB, such as a polymorph of the free base compound or a polymorph of the salt.
  • the solid form of DOC is a polymorph of DOC, such as a polymorph of the free base compound or a polymorph of the salt.
  • the solid form of the compound is a crystalline salt form of the compound, such as an acid addition salt form.
  • the solid form of DOM, DOI, DOB, or DOC comprises a salt of DOM, DOI, DOB, or DOC.
  • Suitable salts include a pharmaceutically acceptable salt of DOM, DOI, DOB, or DOC.
  • the salt is not a hydrochloride salt of DOM, DOI, DOB, or DOC.
  • the salt of DOM, DOI, DOB, or DOC may be formed from a suitable pharmaceutically acceptable acid, including, without limitation, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, benzene sulfonic acid, isethionic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, xinafoic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid
  • the salt of DOM, DOI, DOB, or DOC may be formed from a suitable pharmaceutically acceptable base, including, without limitation, inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
  • Salts derived from pharmaceutically acceptable organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, tris(hydroxymethyl)aminomethane (Tris), ethanolamine, 2-dimethylaminoethanol, 2- diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
  • Tris tris(hydroxymethyl)aminomethane
  • ethanolamine 2-dimethylamin
  • the salt may be formed using an acid from Table 1.
  • the acid is not hydrochloric acid.
  • the acid salts of DOM, DOI, DOB, or DOC disclosed herein can have any suitable stoichiometric ratio of acid to DOM, DOI, DOB, or DOC.
  • the molar ratio of acid to DOM, DOI, DOB, or DOC is from about 0.4 to about 2.2, such as forms wherein the salt has a stoichiometric ratio of acid to DOM, DOI, DOB, or DOC of from about 0.5 to about 2, such as about 0.5, about 1 or about 2.
  • B) Solid forms Embodiments of DOM, DOI, DOB, or DOC of the present disclosure are in a solid form.
  • the solid form may be a crystalline form or an amorphous form.
  • the solid form is a crystalline form, such as a polymorph.
  • the solid form of DOM, DOI, DOB, or DOC is a salt.
  • the solid form is a crystalline salt form of the compound.
  • solid forms of DOM, DOI, DOB, or DOC such as crystalline forms including salt and non-salt crystalline forms of DOM, DOI, DOB, or DOC , may exist in more than one crystal form. Such different forms are referred to as polymorphs.
  • the disclosed compounds are particular polymorphs of DOM or DOM salts.
  • the disclosed compounds are particular polymorphs of DOI or DOI salts. In some embodiments, the disclosed compounds are particular polymorphs of DOB or DOB salts. In some embodiments, the disclosed compounds are particular polymorphs of DOC or DOC salts.
  • the solid form of DOM, DOI, DOB, or DOC disclosed herein is selected to be a crystalline form, such as a particular polymorph of a crystalline form of DOM, DOI, DOB, or DOC that provides one or more desired properties.
  • the crystalline form offers advantages over the amorphous form of the molecule. In another embodiment, the disclosed polymorph offers improved properties as compared to another polymorph of DOM, DOI, DOB, or DOC .
  • the DOM, DOI, DOB, or DOC may be a salt or free base compound.
  • the one or more desired properties may include, but are not limited to, physical properties, including but not limited to, melting point, glass transition temperature, flowability, and/or stability, such as thermal stability, mechanical stability, shelf life, stability against polymorphic transition, etc.; chemical properties, such as, but not limited to, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles; and/or pharmacokinetic properties, such as, but not limited to, bioavailability, absorption, distribution, metabolism, excretion, toxicity including cytotoxicity, dissolution rate, and/or half-life.
  • the desired polymorph may be produced by techniques known to persons of ordinary skill in the art. Such techniques include, but are not limited to, crystallization in particular solvents and/or at particular temperatures, supersaturation, using a precipitation agent, such as a salt, glycol, alcohol, etc., co-crystallization, lyophilization, spray drying, freeze drying, and/or complexing with an inert agent.
  • a precipitation agent such as a salt, glycol, alcohol, etc.
  • co-crystallization such as a salt, glycol, alcohol, etc.
  • lyophilization such as a salt, glycol, alcohol, etc.
  • spray drying such as g., freeze drying, and/or complexing with an inert agent.
  • Techniques to identify a particular solid form of DOM, DOI, DOB, or DOC are known to persons of ordinary skill in the art, and include, but are not limited to, X-ray crystallography, X- ray diffraction, electron crystallography, powder diffraction, including X-ray, neutron, or electron diffraction, X-ray fiber diffraction, small-angle X-ray scattering, and/or melting point.
  • the present disclosure provides solid forms of DOM L-aspartate, e.g., crystalline forms of DOM L-aspartate.
  • the DOM L-aspartate XRPD profile is substantially similar to that shown in FIG. 1.
  • the solid form of DOM L-aspartate is crystalline DOM L-aspartate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.8 °2 ⁇ , 11.3 °2 ⁇ , and 12.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is crystalline DOM L-aspartate characterized, by XRPD signals at 3.8 °2 ⁇ , 11.3 2 ⁇ . and 12.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is crystalline DOM L-aspartate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.8 °2 ⁇ , 7.6 °2 ⁇ , 11.3 °2 ⁇ , 12.4 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is crystalline DOM L- aspartate characterized by XRPD signals at 3.8 °2 ⁇ , 7.6 °2 ⁇ , 11.3 °2 ⁇ , 12.4 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is crystalline DOM L-aspartate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.8 °2 ⁇ , 11.3 °2 ⁇ , and 21.4 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is crystalline DOM L-aspartate characterized by XRPD signals at 3.8 °2 ⁇ , 11.3 °2 ⁇ , and 21.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is crystalline DOM L-aspartate characterized by two or more, or three or more XRPD signals selected from the group consisting of‘3.8 °2 ⁇ , 11.3 °2 ⁇ , 11.8 °2 ⁇ , 21.4 °2 ⁇ , and 21.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is DOM L-aspartate characterized by XRPD signals at 3.8 °2 ⁇ , 11.3 °2 ⁇ , 11.8 °2 ⁇ , 21.4 °2 ⁇ , and 21.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is crystalline DOM L-aspartate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.8 °2 ⁇ , 11.3 °2 ⁇ , 21.4 °2 ⁇ , 21.6 °2 ⁇ , 1 1.8 °2 ⁇ , 23.8 °2 ⁇ , and 12.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is DOM L-aspartate characterized by XRPD signals at 3.8 °2 ⁇ , 11.3 °2 ⁇ , 21.4 °2 ⁇ , 21.6 °2 ⁇ , 11.8 °2 ⁇ , 23.8 °2 ⁇ , and 12.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is cry stalline DOM L-aspartate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.8 °2 ⁇ , 11.3 °2 ⁇ , 21.4 °2 ⁇ , 21.6 °2 ⁇ , 11.8 °2 ⁇ , 23.8 °2 ⁇ , 12.4 °2 ⁇ , 24.3 °2 ⁇ , 26.4 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-aspartate is DOM L-aspartate characterized by XRPD signals at 3.8 °2 ⁇ , 11.3 °2 ⁇ , 21.4 °2 ⁇ , 21.6 °2 ⁇ , 11.8 °2 ⁇ , 23.8 °2 ⁇ , 12.4 °2 ⁇ , 24.3 °2 ⁇ , 26.4 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 20; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM L-aspartate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, or twenty-nine XRPD signals selected from those set forth in Table 2.
  • the present disclosure provides solid forms of DOM adipate, e.g., crystalline forms of DOM adipate.
  • the DOM adipate XRPD profile is substantially similar to that shown in FIG. 2.
  • the DOM adipate 1 H NMR spectrum is substantially similar to that shown in FIG. 24.
  • the DOM adipate TGA profile is substantially similar to that shown in FIG. 25.
  • the DOM adipate DSC profile is substantially similar to that shown in FIG. 25.
  • the solid form of DOM adipate is crystalline DOM adipate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °2 ⁇ , .12.8 °2 ⁇ , and .15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by XRPD signals at 9.4 °2 ⁇ , 12,8 °2 ⁇ , and 1.5.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °2 ⁇ , 12.8 °2 ⁇ , 15.1 °2 ⁇ , 16.5 °2 ⁇ , and 17.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by XRPD signals at 9.4 °2 ⁇ , 12.8 °2 ⁇ , 15.1 °2 ⁇ , 16.5 °2 ⁇ , and 17.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.1 °2 ⁇ , 22.5 °2 ⁇ , and 23.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ O.O °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by XRPD signals at 15.1 °2 ⁇ , 22.5 °2 ⁇ , and 23.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ O.O °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.1 °2 ⁇ , 16.5 °2 ⁇ , 22.0 °2 ⁇ . 22.5 °2 ⁇ , and 23.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or .0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is DOM adipate characterized by XRPD signals at 15.1 °2 ⁇ , 16.5 °2 ⁇ , 22.0 °2 ⁇ , 22.5 °2 ⁇ , and 23.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 15.1 °2 ⁇ , 23.0 °2 ⁇ , 22.5 °2 ⁇ , 22.0 °2 ⁇ , 16.5 °2 ⁇ , 9.4 °2 ⁇ , and 15.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is DOM adipate characterized by XRPD signals at 15.1 °2 ⁇ , 23.0 °2 ⁇ , 22.5 °2 ⁇ , 22.0 °2 ⁇ , 16.5 °2 ⁇ , 9.4 °2 ⁇ , and. 15.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is crystalline DOM adipate characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.1 °2 ⁇ , 23.0 °2 ⁇ , 22.5 °2 ⁇ , 22.0 °2 ⁇ , 16.5 °2 ⁇ , 9.4 °2 ⁇ , 15.3 °2 ⁇ , 21.6 °2 ⁇ , 25.2 °2 ⁇ , and 18.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM adipate is DOM adipate characterized by XRPD signals at 15.1 °2 ⁇ , 23.0 °2 ⁇ , 22,5 °2 ⁇ , 22.0 °2 ⁇ , 16.5 °2 ⁇ , 9.4 °2 ⁇ , 15.3 °2 ⁇ , 21.6 °2 ⁇ , 25.2 °2 ⁇ , and 18.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM adipate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, forty-eight, forty-nine, or fifty XRPD signals selected from those set forth in Table 3.
  • the present disclosure provides solid, forms of DOM benzenesulfonate (besylate), e.g., crystalline forms of DOM benzenesulfonate.
  • the DOM benzenesulfonate XRPD profile is substantially similar to that shown in FIGs. 3 or 62.
  • the DOM benzenesulfonate ' H NMR spectrum is substantially similar to that shown in FIG. 26.
  • the DOM benzenesulfonate TGA profile is substantially similar to that shown in FIG. 27.
  • the DOM benzenesulfonate DSC profile is substantially similar to that shown in FIG. 27,
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.5 °2 ⁇ , 9.1 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by XRPD signals at. 5.5 °2 ⁇ , 9.1 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.5 °2 ⁇ , 9.1 °2 ⁇ , 10.6 °2 ⁇ , l l.O °2 ⁇ , and 17.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by XRPD signals at 5.5 °2 ⁇ , 9.1 °2 ⁇ , 10.6 °2 ⁇ , 11.0 °2 ⁇ , and 17.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ . ⁇ 0.1 °2 ⁇ : or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.0 °2 ⁇ , 18.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by XRPD signals at 11.0 °2 ⁇ , 18.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.1 °2 ⁇ , 11.0 °2 ⁇ , 16.2 °2 ⁇ , 18.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is DOM benzenesulfonate characterized by XRPD signals at 9.1 °2 ⁇ , 11.0 °2 ⁇ , 16.2 °2 ⁇ , 18.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is cry stalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.3 °2 ⁇ , 18.2 °2 ⁇ , 11.0 °2 ⁇ , 9.1 °2 ⁇ , 16.2 °2 ⁇ , 19.2 °2 ⁇ , and 5.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is DOM benzenesulfonate characterized by XRPD signals at 20.3 °2 ⁇ , 18.2 °2 ⁇ , 11.0 °2 ⁇ , 9.1 °2 ⁇ , 16.2 °2 ⁇ , 19.2 °2 ⁇ , and 5.5 29 ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.3 °2 ⁇ , 18.2 °2 ⁇ , 11.0 °2 ⁇ , 9.1 °2 ⁇ , 16.2 °2 ⁇ , 19.2 °2 ⁇ , 5.5 °2 ⁇ , 17.7 °2 ⁇ , 21.8 °2 ⁇ , and 24,6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is DOM benzenesulfonate characterized by XRPD signals at 20.3 °2 ⁇ , 18.2 °2 ⁇ , 11.0 °2 ⁇ , 9.1 °2 ⁇ , 16.2 °2 ⁇ , 19.2 °2 ⁇ , 5.5 °2 ⁇ , 17.7 °2 ⁇ , 21.8 °2 ⁇ , and 24.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM benzenesulfonate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, or thirty-eight XRPD signals selected from those set forth in Table 4.
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.1 °2 ⁇ , 19.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or . ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by XRPD signals at 9. 1 °2 ⁇ , 19.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.1 °2 ⁇ , 11.0 °2 ⁇ , 18.2 °2 ⁇ , 19.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is DOM benzenesulfonate characterized by XRPD signals at 9.1 °2 ⁇ , 11.0 °2 ⁇ , 18.2 °2 ⁇ , 19.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is cry stalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.1 °2 ⁇ , 20.3 °2 ⁇ , 19.2 °2 ⁇ , 18.2 °2 ⁇ , 11.0 °2 ⁇ , 24.9 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM benzenesulfonate is DOM benzenesulfonate characterized by XRPD signals at 9.1 °2 ⁇ , 20.3 °2 ⁇ ,
  • the solid form of DOM benzenesulfonate is crystalline DOM benzenesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.1 °2 ⁇ , 20.3 °2 ⁇ , 19.2 °2 ⁇ , 18.2 °2 ⁇ , 11.0 °2 ⁇ , 24.9 °2 ⁇ , 10.6 °2 ⁇ , 21.8 °2 ⁇ ,
  • the solid form of DOM benzenesulfonate is DOM benzenesulfonate characteri zed by XRPD signals at 9.1 °2 ⁇ , 20.3 °2 ⁇ , 19.2 °2 ⁇ , 18.2 °2 ⁇ , 1 1.0 °2 ⁇ , 24.9 °2 ⁇ , 10.6 °2 ⁇ , 21.8 °2 ⁇ , 16.2 °2 ⁇ , and 5.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM benzenesulfonate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, forty-eight, forty-nine, fifty, fifty-one, fifty-two, or fifty -three XRPD signals selected from those set forth in Table 5.
  • the present disclosure provides solid forms of DOM fumarate Form 1 , e.g., crystalline forms of DOM fumarate.
  • the DOM fumarate Form 1 XRPD profile is substantially similar to that shown in FIG. 4.
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °2 ⁇ . 9.8 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by XRPD signals at 4.9 °2 ⁇ , 9.8 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °2 ⁇ , 9.8 °2 ⁇ , 10.6 °2 ⁇ , 14.6 °2 ⁇ , and 21.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by XRPD signals at 4.9 °2 ⁇ , 9.8 °2 ⁇ , 10.6 °2 ⁇ , 14.6 °2 ⁇ , and. 21.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °2 ⁇ , 9.8 °2 ⁇ , and 25.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by XRPD signals at 4,9 °2 ⁇ , 9.8 °2 ⁇ , and 25.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.9 °2 ⁇ , 9.8 °2 ⁇ , 14.6 °2 ⁇ , 21.6 °2 ⁇ , and 25.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ . ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is DOM fumarate Form 1 characterized by XRPD signals at 4.9 °2 ⁇ , 9.8 °2 ⁇ , 14.6 °2 ⁇ , 21.6 °2 ⁇ , and 25.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.8 °2 ⁇ , 4.9 °2 ⁇ , 25.0 °2 ⁇ , 21.6 °2 ⁇ , 14.6 °2 ⁇ , 10.6 °2 ⁇ , and 19.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is DOM fumarate Form 1 characterized by XRPD signals at 9.8 °2 ⁇ , 4.9 °2 ⁇ , 25.0 °2 ⁇ , 21.6 °2 ⁇ , 14.6 °2 ⁇ , 10.6 °2 ⁇ , and 19.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is crystalline DOM fumarate Form 1 characterized, by two or more, or three or more XRPD signals selected from the group consisting of 9.8 °2 ⁇ , 4.9 °2 ⁇ , 25.0 °2 ⁇ , 21.6 °2 ⁇ , 14.6 °2 ⁇ , 10.6 °2 ⁇ , 19.3 °2 ⁇ , 19.5 °2 ⁇ , 23.9 °2 ⁇ , and 19.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 1 is DOM fumarate Form 1 characterized by XRPD signals at 9.8 °2 ⁇ , 4.9 °2 ⁇ , 25.0 °2 ⁇ , 21.6 °2 ⁇ , 14.6 °2 ⁇ , 10.6 °2 ⁇ , 19.3 °2 ⁇ , 19.5 °2 ⁇ , 23.9 °2 ⁇ , and 19.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM fumarate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, or thirty XRPD signals selected from those set forth in Table 6.
  • the present disclosure provides solid forms of DOM fumarate Form 2, e.g., crystalline forms of DOM fumarate Form 2.
  • the DOM fumarate Form 2 XRPD profile is substantially similar to that shown in FIG. 63.
  • the solid form of DOM fumarate Form 2 is crystalline DOM fumarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.2 °2 ⁇ . 4.7 °2 ⁇ , and 10.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is crystalline DOM fumarate Form 2 characterized by XRPD signals at 4.2 °2 ⁇ , 4.7 °2 ⁇ , and 10.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is crystalline DOM fumarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.2 °2 ⁇ , 4.7 °2 ⁇ , 10.3 °2 ⁇ , 12.7 °2 ⁇ , and 15.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is crystalline DOM fumarate Form 2 characterized by XRPD signals at 4.2 °2 ⁇ , 4.7 °2 ⁇ , 10.3 °2 ⁇ ,
  • the solid form of DOM fumarate Form 2 is crystalline DOM fumarate Form 2 characterized by two or more, or three or more XR PD signals selected from the group consisting of 4.7 °2 ⁇ . 12.7 °2 ⁇ , and 15.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is crystalline DOM fumarate Form 2 characterized by XRPD signals at 4.7 °2 ⁇ , 12.7 °2 ⁇ , and 15.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is ciystalline DOM fumarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.7 °2 ⁇ , 12.7 29. 15.8 °2 ⁇ , 25.5 26. and 4.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is DOM fumarate Form 2 characterized by XRPD signals at 4.7 °2 ⁇ , 12.7 °2 ⁇ , 15.8 °2 ⁇ , 25.5 °2 ⁇ , and. 4.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is ciystalline DOM fumarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.7 °2 ⁇ , 12.7 °2 ⁇ , 15.8 °2 ⁇ , 25.5 °2 ⁇ , 4.2 °2 ⁇ , 25.1 °2 ⁇ , and 19.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM fumarate Form 2 is DOM fumarate Form 2 characterized by XRPD signals at 4.7 °2 ⁇ , 12.7 °2 ⁇ ,
  • the solid form of DOM fumarate Form 2 is crystalline DOM fumarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.7 °2 ⁇ , 12.7 °2 ⁇ , 15.8 °2 ⁇ , 25.5 °2 ⁇ , 4.2 °2 ⁇ , 25.1 °2 ⁇ , 19.1 °2 ⁇ , 20.8 °2 ⁇ ,
  • the solid form of DOM fumarate Form 2 is DOM fumarate Form 2 characterized by XRPD signals at 4.7 °2 ⁇ , 12.7 °2 ⁇ , 15.8 °2 ⁇ , 25.5 °2 ⁇ , 4.2 °2 ⁇ , 25.1 °2 ⁇ , 19.1 °2 ⁇ , 20.8 °2 ⁇ , 22.8 °2 ⁇ , and 14.2 °2 ⁇ (. ⁇ 0.2 °2 ⁇ ; . ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM fumarate Form 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, or thirty-nine XRPD signals selected from those set forth in Table 7.
  • the present disclosure provides solid forms of DOM gentisate, e.g., crystalline forms of DOM gentisate.
  • the DOM gentisate XRPD profile is substantially similar to that shown in FIG. 5.
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 13.2 °2 ⁇ , 13.9 °2 ⁇ , and 17.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by XRPD signals at 13.2 °2 ⁇ , 13.9 20. and 17.6 20 ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 13.2 °2 ⁇ , 13.9 °2 ⁇ , 15.5 °2 ⁇ , 17.6 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by XRPD signals at 13.2 °2 ⁇ , 13.9 °2 ⁇ , 15.5 °2 ⁇ , 17.6 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.6 °2 ⁇ , 26.5 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ , Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by XRPD signals at 17.6 °2 ⁇ , 26.5 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.6 °2 ⁇ , 26.5 °2 ⁇ , 22.0 °2 ⁇ , 23.5 °2 ⁇ , and 15.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is DOM gentisate characterized by XRPD signals at 17.6 °2 ⁇ , 26.5 °2 ⁇ , 22.0 °2 ⁇ , 23.5 °2 ⁇ , and 15.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.6 °2 ⁇ , 26.5 °2 ⁇ , 22.0 °2 ⁇ , 23.5 °2 ⁇ , 15.5 °2 ⁇ , 18.4 °2 ⁇ , and 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is DOM gentisate characterized by XRPD signals at 17.6 °2 ⁇ , 26.5 °2 ⁇ , 22.0 °2 ⁇ , 23.5 °2 ⁇ , 15.5 °2 ⁇ , 18.4 °2 ⁇ , and 23.9 °2 ⁇ (. ⁇ 0.2 °2 ⁇ ; . ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is crystalline DOM gentisate characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.6 °2 ⁇ , 26.5 °2 ⁇ , 22.0 °2 ⁇ , 23.5 °2 ⁇ , 15.5 °2 ⁇ , 18.4 °2 ⁇ , 23.9 °2 ⁇ , 13.2 °2 ⁇ , 13.9 °2 ⁇ , and 22.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM gentisate is DOM gentisate characterized by XRPD signals at 17.6 °2 ⁇ , 26.5 °2 ⁇ , 22.0 °2 ⁇ , 23.5 29. 15.5 °2 ⁇ , 18.4 °2 ⁇ , 23.9 °2 ⁇ . 13.2 °2 ⁇ , 13.9 °2 ⁇ . and 22.3 °2 ⁇ ( ⁇ 0.2 29; ⁇ 0.1 29: or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM gentisate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen XRPD signals selected from those set forth in Table 8.
  • the present disclosure provides solid forms of DOM glutamate, e.g., crystalline forms of DOM glutamate.
  • the DOM glutamate XRPD profile is substantially similar to that shown in FIG. 6.
  • the DOM glutamate ] H NMR spectrum is substantially similar to that shown in FIG. 30.
  • the DOM glutamate TGA profile is substantially similar to that shown in FIG. 31.
  • the DOM glutamate DSC profile is substantially similar to that shown in FIG. 31.
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.4 °2 ⁇ , 9.9 °2 ⁇ , and 13.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by XRPD signals at 3.4 °2 ⁇ , 9.9 °2 ⁇ , and 13.2 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.4 °2 ⁇ , 9.9 °2 ⁇ , 13.2 °2 ⁇ , 16.6 °2 ⁇ , and 17.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by XRPD signals at 3.4 °2 ⁇ , 9.9 °2 ⁇ , 13.2 °2 ⁇ , 16.6 °2 ⁇ , and 17.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ;
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.4 °2 ⁇ , 26.6 °2 ⁇ , and 17.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by XRPD signals at 3.4 °2 ⁇ , 26.6 °2 ⁇ , and 17.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.4 °2 ⁇ , 26.6 °2 ⁇ , 17.0 °2 ⁇ , 25.5 °2 ⁇ , and 13.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is DOM glutamate characterized by XRPD signals at 3.4 °2 ⁇ , 26.6 °2 ⁇ , 17.0 °2 ⁇ , 25.5 °2 ⁇ , and 13.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.4 °2 ⁇ , 26.6 °2 ⁇ , 17.0 °2 ⁇ , 25.5 °2 ⁇ , 13.2 °2 ⁇ , 9.9 °2 ⁇ , and 33.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is DOM glutamate characterized by XRPD signals at 3.4 °2 ⁇ , 26.6 °2 ⁇ , 17.0 °2 ⁇ , 25.5 °2 ⁇ , 13.2 °2 ⁇ , 9.9 °2 ⁇ , and 33.4 °2 ⁇ (. ⁇ 0.2 °2 ⁇ ; . ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is crystalline DOM glutamate characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.4 °2 ⁇ , 26.6 °2 ⁇ , 17.0 °2 ⁇ , 25.5 °2 ⁇ , 13.2 °2 ⁇ , 9.9 °2 ⁇ , 33.4 °2 ⁇ , 25.2 °2 ⁇ , 30.0 °2 ⁇ , and 22.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutamate is DOM glutamate characterized, by XRPD signals at 3.4 °2 ⁇ , 26.6 °2 ⁇ , 17.0 °2 ⁇ , 25.5 °2 ⁇ , 13.2 °2 ⁇ , 9.9 °2 ⁇ , 33.4 °2 ⁇ , 25.2 °2 ⁇ , 30.0 °2 ⁇ , and 22.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM glutamate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, or thirty-nine XRPD signals selected from those set forth in Table 9.
  • the present disclosure provides solid forms of DOM glutarate Form 1 , e.g., crystalline forms of DOM glutarate Form 1.
  • the DOM glutarate Form 1 XRPD profile is substantially similar to that shown in FIG. 7.
  • the DOM glutarate Form 1 l H NMR spectrum is substantially similar to that shown in FIG. 32.
  • the DOM glutarate Form 1 TGA profile is substantially similar to that shown m FIG. 33.
  • the DOM glutarate Form 1 DSC profile is substantially similar to that shown in FIG. 33.
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 5.9 °2 ⁇ , and 8.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by XRPD signals at 4.1 °2 ⁇ , 5.9 °2 ⁇ , and 8.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ . 5.9 °2 ⁇ , 8.1 °2 ⁇ , 9.0 °2 ⁇ , and 12.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by XRPD signals at 4.1 °2 ⁇ , 5.9 °2 ⁇ , 8.1 °2 ⁇ , 9.0 °2 ⁇ , and 12.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.1 °2 ⁇ , 21.8 °2 ⁇ , and 5.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by XRPD signals at 12.1 °2 ⁇ , 21.8 °2 ⁇ , and 5.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12. 1 °2 ⁇ , 21.8 °2 ⁇ , 5.9 °2 ⁇ , 18.6 °2 ⁇ , and 8,1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is DOM glutarate Form 1 characterized by XRPD signals at 12.1 °2 ⁇ , 21.8 °2 ⁇ , 5.9 °2 ⁇ , 18.6 °2 ⁇ , and 8.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.1 °2 ⁇ , 21.8 °2 ⁇ , 5.9 °2 ⁇ , 18.6 °2 ⁇ , 8.1 °2 ⁇ , 22.5 °2 ⁇ , and 15.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is DOM glutarate Form 1 characterized by XRPD signals at 12.1 °2 ⁇ , 21.8 °2 ⁇ , 5.9 °2 ⁇ , 18.6 °2 ⁇ , 8.
  • the solid form of DOM glutarate Form 1 is crystalline DOM glutarate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.1 °2 ⁇ , 21.8 °2 ⁇ , 5.9 °2 ⁇ , 18.6 °2 ⁇ , 8.1 °2 ⁇ , 22.5 °2 ⁇ , 15.4 °2 ⁇ , 4.1 °2 ⁇ , 23.7 °2 ⁇ , and 14.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 1 is DOM glutarate Form 1 characterized by XR PD signals at 12.1 °2 ⁇ , 21.8 °2 ⁇ , 5.9 °2 ⁇ , 18.6 °2 ⁇ , 8.1 °2 ⁇ , 22.5 °2 ⁇ , 15.4 °2 ⁇ , 4.1 °2 ⁇ , 23.7 °2 ⁇ , and 14.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM glutarate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, or forty-eight XRPD signals selected from those set forth in Table 10.
  • the present disclosure provides solid, forms of DOM glutarate Form 2, e.g., crystalline forms of DOM glutarate Form 2.
  • the DOM glutarate Form 2 XRPD profile is substantially similar to that shown in FIG. 64.
  • the DOM glutarate Form 2 NMR spectrum is substantially similar to that shown in FIG. 34.
  • the DOM glutarate Form 2 TGA profile is substantially similar to that shown in FIG, 35.
  • the DOM glutarate Form 2 DSC profile is substantially similar to that shown in FIG. 35,
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.1 °2 ⁇ , 8.5 °2 ⁇ , and 10.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by XRPD signals at 6. 1 °2 ⁇ , 8.5 °2 ⁇ , and 10.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.1 °2 ⁇ , 8.5 °2 ⁇ . 10.5 °2 ⁇ , 12.1 °2 ⁇ , and 19.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by XRPD signals at 6.1 °2 ⁇ , 8.5 °2 ⁇ , 10.5 °2 ⁇ , 12.1 °2 ⁇ , and 19.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.1 °2 ⁇ , 16.4 °2 ⁇ , and 19.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized, by XRPD signals at 6.1 °2 ⁇ , 16.4 °2 ⁇ , and. 19.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6, 1 °2 ⁇ , 16.4 °2 ⁇ , 19.8 °2 ⁇ , 15.6 °2 ⁇ , and 21.0 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1. radiation).
  • the solid form of DOM glutarate Form 2 is DOM glutarate Form 2 characterized by XRPD signals at 6.1 °2 ⁇ , 16.4 °2 ⁇ , 19.8 °2 ⁇ , 1.5.6 °2 ⁇ , and 21.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1. radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.1 °2 ⁇ , 16.4 °2 ⁇ , 19.8 °2 ⁇ , 15.6 °2 ⁇ , 21.0 °2 ⁇ , 8.5 °2 ⁇ , and 16.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is DOM glutarate Form 2 characterized by XRPD signals at 6.1 °2 ⁇ , 16.4 °2 ⁇ , 19.8 °2 ⁇ , 15.6 °2 ⁇ , 21.0 °2 ⁇ , 8.5 °2 ⁇ , and 16.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is crystalline DOM glutarate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.1 °2 ⁇ , 16.4 °2 ⁇ , 19.8 °2 ⁇ , 15.6 °2 ⁇ , 21.0 °2 ⁇ , 8.5 °2 ⁇ , 16.0 °2 ⁇ , 12.1 °2 ⁇ , 23.2 °2 ⁇ , and 23.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ . ⁇ 0.1 °2 ⁇ . or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glutarate Form 2 is DOM glutarate Form 2 characterized by XRPD signals at 6.1 °2 ⁇ , 16.4 °2 ⁇ , 19.8 °2 ⁇ , 15.6 °2 ⁇ , 21.0 °2 ⁇ , 8.5 °2 ⁇ , 16.0 °2 ⁇ , 12.1 °2 ⁇ , 23.2 °2 ⁇ , and 23.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM glutarate Form 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, forty-eight, forty-nine, fifty, fifty-one, fifty-two, fifty-three, fifty-four, fifty-five, or fifty-six XRPD signals selected from those set forth in Table 11.
  • the present disclosure provides solid forms of DOM glycolate Form 1, e.g., crystalline forms of DOM glycolate Form 1.
  • the DOM glycolate Form 1 XRPD profile is substantially similar to that shown in FIG. 8.
  • the DOM glycolate Form 1 l H NMR spectrum is substantially similar to that shown in FIG. 36.
  • the DOM glycolate Form 1 TGA profile is substantially similar to that shown in FIG. 37.
  • the DOM glycolate Form 1 DSC profile is substantially similar to that shown in FIG. 37.
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.1 °2 ⁇ . 10.1 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by XRPD signals at 5.1 °2 ⁇ , 10.1 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.1 °2 ⁇ , 10.1 29. 15.1 °2 ⁇ , 20.2 29. and 25.3 29 ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by XRPD signals at 5.1 °2 ⁇ , 10.1 °2 ⁇ , 15.1 °2 ⁇ , 20.2 °2 ⁇ , and. 25.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.1 °2 ⁇ , 15.1 °2 ⁇ , and 20.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by XRPD signals at 5. 1 °2 ⁇ , 15.1 °2 ⁇ , and 20.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.1 °2 ⁇ , 15.1 °2 ⁇ , 20.2 °2 ⁇ , 25.3 °2 ⁇ , 10. 1 °2 ⁇ , 22.6 °2 ⁇ , and 14.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM glycolate Form 1 is DOM glycolate Form 1 characterized by XRPD signals at 5.1 °2 ⁇ , 15.1 °2 ⁇ ,
  • the solid form of DOM glycolate Form 1 is crystalline DOM glycolate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.1 °2 ⁇ . 15.1 °2 ⁇ , 20.2 °2 ⁇ , 25.3 °2 ⁇ , 10.1 °2 ⁇ , 22.6 °2 ⁇ , 14.2 °2 ⁇ , 18.1 °2 ⁇ .
  • the solid form of DOM glycolate Form 1 is DOM glycolate Form 1 characterized by XRPD signals at 5.1 °2 ⁇ , 15.1 °2 ⁇ , 20.2 °2 ⁇ , 25.3 °2 ⁇ , 10.1 °2 ⁇ , 22.6 °2 ⁇ , 14.2 °2 ⁇ , 18.1 °2 ⁇ , 24.3 °2 ⁇ , and 17.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM glycolate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, or twenty-five XRPD signals selected from those set forth in Table 12.
  • the present disclosure provides solid forms of DOM hydrochloride, e.g., crystalline forms of DOM hydrochloride.
  • the DOM hydrochloride XRPD profile is substantially similar to that shown in FIG. 9.
  • the DOM hydrochloride 1 H NMR spectrum is substantially similar to that shown in FIG. 38.
  • the DOM hydrochloride TGA profile is substantially similar to that shown in FIG. 39.
  • the DOM hydrochloride DSC profile is substantially similar to that shown in FIG. 39.
  • the solid form of DOM hydrochloride is crystalline DOM hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.9 °2 ⁇ , 13.3 °2 ⁇ , and 14.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM hy drochloride is crystalline DOM hydrochloride characterized by XRPD signals at 8.9 °2 ⁇ , 13.3 °2 ⁇ , and 14.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is crystalline DOM hydrochloride characterized by two or more, or three or more XRI’D signals selected from the group consisting of 8.9 °2 ⁇ , 13.3 °2 ⁇ , 14.4 °2 ⁇ , 15.9 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is crystalline DOM hydrochloride characterized by XRPD signals at 8.9 °2 ⁇ , 13.3 °2 ⁇ , 14/4 °2 ⁇ , 15,9 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is crystalline DOM hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 8,9 °2 ⁇ , 26.7 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is crystalline DOM hydrochloride characterized by XRPD signals at 8.9 °2 ⁇ , 26.7 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is crystalline DOM hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.9 °2 ⁇ , 26.7 °2 ⁇ , 15.9 °2 ⁇ , 22.8 °2 ⁇ , and 25.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is DOM hydrochloride characterized by XRPD signals at 8.9 °2 ⁇ , 26.7 °2 ⁇ , 15.9 °2 ⁇ , 22.8 °2 ⁇ , and 25.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hy drochloride is crystalline DOM hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.9 °2 ⁇ , 26.7 °2 ⁇ , 15.9 °2 ⁇ , 22.8 °2 ⁇ , 25.2 °2 ⁇ , 16.7 °2 ⁇ , and 17.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is DOM hydrochloride characterized by XRPD signals at 8.9 °2 ⁇ , 26.7 °2 ⁇ , 15.9 °2 ⁇ , 22.8 °2 ⁇ , 25.2 °2 ⁇ , 16.7 °2 ⁇ , and 17.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ : or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is crystalline DOM hydrochloride characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.9 °2 ⁇ , 26.7 °2 ⁇ , 15.9 °2 ⁇ , 22.8 °2 ⁇ , 25.2 °2 ⁇ , 16.7 °2 ⁇ , 17.7 °2 ⁇ , 27.0 °2 ⁇ , 25.9 °2 ⁇ , and 30.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ . ⁇ 0.1 °2 ⁇ : or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM hydrochloride is DOM hydrochloride characterized by XRPD signals at 8.9 °2 ⁇ , 26.7 °2 ⁇ , 15.9 °2 ⁇ , 22.8 °2 ⁇ , 25.2 °2 ⁇ , 16.7 °2 ⁇ , 17.7 °2 ⁇ , 27.0 °2 ⁇ , 25.9 °2 ⁇ , and 30.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM hydrochloride is characterized, by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, or thirty-seven XRPD signals selected from those set forth in Table 13.
  • the present disclosure provides solid forms of DOM l -hydroxy-2- naphthoate (xinafoate), e.g., crystal line forms of DOM 1 -hydroxy-2-naphthoate.
  • the DOM 1 -hydroxy-2-naphthoate XRPD profile is substantially similar to that shown in FIG. 10.
  • the DOM 1 -hydroxy-2-naphthoate 1 H NMR spectrum is substantially similar to that shown in FIG. 60.
  • the DOM 1 -hydroxy-2- naphthoate TGA profile is substantially similar to that shown in FIG. 61 .
  • the DOM l-hydroxy-2-naphthoate DSC profile is substantially similar to that shown in FIG. 61 .
  • the solid form of DOM l-hydroxy-2-naphthoate is crystalline DOM l-hydroxy-2-naphthoate characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °2 ⁇ , 10.0 °2 ⁇ , and 16.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM 1 -hydroxy-2-naphthoate is crystalline DOM 1 -hydroxy-2-naphthoate characterized by XRPD signals at 5.0 °2 ⁇ , 10.0 °2 ⁇ , and 16.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM 1 -hydroxy -2-naphthoate is crystalline DOM 1 -hydroxy -2-naphthoate characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °2 ⁇ , 10.0 °2 ⁇ , 16.6 °2 ⁇ , 18.1 °2 ⁇ , and 24.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM l-hydroxy-2- naphthoate is crystalline DOM 1 -hydroxy-2-naphthoate characterized by XRPD signals at 5.0 °2 ⁇ , 10.0 °2 ⁇ , 16.6 °2 ⁇ , 18.1 °2 ⁇ . and 24.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM 1 -hydroxy -2-naphthoate is crystalline DOM 1 -hydroxy -2-naphthoate characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.0 °2 ⁇ , 16.6 °2 ⁇ , and 24.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM 1 -hydroxy-2-naphthoate is crystalline DOM l-hydroxy-2-naphthoate characterized by XRPD signals at 10.0 °2 ⁇ , 16.6 °2 ⁇ , and 24.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM 1 -hydroxy-2-naphthoate is crystalline DOM l-hydroxy-2-naphthoate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 10.0 °2 ⁇ , 16.6 °2 ⁇ , 24.4 °2 ⁇ , 18.1 °2 ⁇ , and 21.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM l-hydroxy-2- naphthoate is DOM l-hydroxy-2-naphthoate characterized by XRPD signals at 10.0 °2 ⁇ , 16.6 °2 ⁇ ,
  • the solid form of DOM l-hydroxy-2-naphthoate is crystalline DOM 1 -hydroxy -2-naphthoate characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.0 °2 ⁇ , 16.6 °2 ⁇ , 24,4 °2 ⁇ , 18.1 °2 ⁇ , 21.5 °2 ⁇ , 5.0 °2 ⁇ , and 26.4- °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM l-hydroxy-2-naphthoate is DOM l-hydroxy-2-naphthoate characterized by XRPD signals at 10.0 °2 ⁇ , 16.6 °2 ⁇ , 24.4 °2 ⁇ , 18.1 °2 ⁇ , 21.5 °2 ⁇ , 5.0 °2 ⁇ , and 26.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM 1 -hydroxy -2-naphthoate is crystalline DOM 1 -hydroxy -2-naphthoate characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.0 °2 ⁇ , 16.6 °2 ⁇ , 24.4 °2 ⁇ , 18.1 °2 ⁇ , 21.5 °2 ⁇ , 5.0 °2 ⁇ , 26.4 °2 ⁇ ,
  • the solid form of DOM l-hydroxy-2-naphthoate is DOM l-hydroxy-2-naphthoate characterized by XRPD signals at 10.0 °2 ⁇ , 16.6 °2 ⁇ , 24.4 °2 ⁇ , 18.1 °2 ⁇ , 21.5 °2 ⁇ , 5.0 °2 ⁇ , 26.4 °2 ⁇ . 23.4 °2 ⁇ . 25.1 °2 ⁇ , and 18.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the crystalline DOM l-hydroxy-2-naphthoate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty- one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, forty-eight, forty-nine, fifty, or fifty-one XRPD signals selected from those set forth in Table 14.
  • the present disclosure provides solid forms of DOM maleate Form
  • the DOM maleate Form 1 e.g., crystalline forms of DOM maleate Form 1 .
  • the DOM maleate Form 1 XRPD profile is substantially similar to that shown in FIG. 65.
  • the DOM maleate Form 1 NMR spectrum is substantially similar to that shown in FIG. 44.
  • the DOM maleate Form 1 TGA profile is substantially similar to that shown in FIG. 45.
  • the DOM maleate Form 1 DSC profile is substantially similar to that shown in FIG. 45.
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.7 °2 ⁇ , 11.5 °2 ⁇ , and 14.0 °2 ⁇ (+0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or . ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by XRPD signals at 4.7 °2 ⁇ , 11.5 °2 ⁇ , and 14.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.7 °2 ⁇ , 11.5 °2 ⁇ , 14.0 °2 ⁇ , 16.4 °2 ⁇ , and 18.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by XRPD signals at 4.7 °2 ⁇ , 11.5 °2 ⁇ , 14.0 °2 ⁇ , 16.4 °2 ⁇ , and 18.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by two or more, or three or more XR PD signals selected from the group consisting of 18.7 °2 ⁇ , 14.0 °2 ⁇ , and 22.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by XRPD signals at 18.7 °2 ⁇ , 14.0 °2 ⁇ , and 22.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.7 °2 ⁇ , 14.0 °2 ⁇ , 22.8 °2 ⁇ , 23.6 °2 ⁇ , and. 19.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by XRPD signals at 18.7 °2 ⁇ , 14.0 °2 ⁇ , 22.8 °2 ⁇ , 23.6 °2 ⁇ , and 19,9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.7 °2 ⁇ , 14.0 °2 ⁇ , 22.8 °2 ⁇ , 23.6 °2 ⁇ , 19.9 °2 ⁇ , 25.1 °2 ⁇ , and 18.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is DOM maleate Form 1 characterized by XRPD signals at 18.7 °2 ⁇ , 14.0 °2 ⁇ , 22.8 °2 ⁇ ,
  • the solid form of DOM maleate Form 1 is crystalline DOM maleate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.7 °2 ⁇ , 14.0 °2 ⁇ , 22.8 °2 ⁇ , 23.6 °2 ⁇ , 19.9 °2 ⁇ , 25.1 °2 ⁇ , 18.3 °2 ⁇ , 16.4 °2 ⁇ , 20.4 °2 ⁇ , and 22.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 1 is DOM maleate Form 1 characterized by XRPD signals at
  • the crystalline DOM maleate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, or twenty-eight XRPD signals selected from those set forth in Table 15.
  • the present disclosure provides solid forms of DOM maleate Forms
  • the XRPD profile of a mixture of DOM maleate Forms 1 and 2 is substantially similar to that shown in FIG. 12.
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.6 °2 ⁇ , 11.5 °2 ⁇ , and 13.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or . ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by XRPD signals at 4.6 °2 ⁇ , 11.5 °2 ⁇ , and 13.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized, by two or more, or three or more XRPD signals selected from the group consisting of 4.6 °2 ⁇ , 11.5 °2 ⁇ , 13.7 °2 ⁇ , 14.9 °2 ⁇ , and 16.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized, by XRPD signals at 4.6 °2 ⁇ ,
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.8 °2 ⁇ , 23.6 °2 ⁇ , and 25.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by XRPD signals at 22.8 °2 ⁇ , 23.6 °2 ⁇ , and 25. 1 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.8 °2 ⁇ , 23.6 °2 ⁇ , 25.1 °2 ⁇ , 16.4 °2 ⁇ , and 22.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate is a. mixture of crystalline DOM maleate Forms 1 and 2 characterized by XRPD signals at 22.8 °2 ⁇ ,
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.8 °2 ⁇ , 23.6 °2 ⁇ , 25.1 °2 ⁇ , 16.4 °2 ⁇ , 22.4 °2 ⁇ , 4.6 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or . ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by XRPD signals at 22.8 °2 ⁇ , 23.6 °2 ⁇ , 25.1 °2 ⁇ , 16.4 °2 ⁇ , 22.4 °2 ⁇ , 4.6 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.8 °2 ⁇ , 23.6 °2 ⁇ , 25.1 °2 ⁇ , 16.4 °2 ⁇ , 22.4 °2 ⁇ , 4.6 °2 ⁇ , 16.7 °2 ⁇ , 18.3 °2 ⁇ , 26.7 °2 ⁇ , and 13.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM' maleate is a mixture of crystalline DOM maleate Forms 1 and 2 characterized by XRPD signals at 22.8 °2 ⁇ , 23.6 °2 ⁇ , 25.1 °2 ⁇ , 16.4 °2 ⁇ , 22.4 °2 ⁇ , 4.6 °2 ⁇ , 16.7 °2 ⁇ , 18.3 °2 ⁇ , 26.7 °2 ⁇ , and 13.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the mixture of crystalline DOM maleate Forms 1 and 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty- three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nme, thirty, thirty- one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, or forty-four XRPD signals selected from those set forth in Table 16,
  • the solid form of DOM maleate Form 2 is crystalline DOM maleate Form 2 characterized by two or more, or three or more XRPD signals selected, from the group consisting of 16.7 °2 ⁇ , 13.7 °2 ⁇ , and 14.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 2 is crystalline DOM maleate Form 2 characterized by XRPD signals at 16.7 °2 ⁇ , 13.7 °2 ⁇ , and 14.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 2 is crystalline DOM maleate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.7 °2 ⁇ , 13.7 °2 ⁇ , 14.9 °2 ⁇ , 17.1 °2 ⁇ , and 17.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 2 is crystalline DOM maleate Form 2 characterized by XRPD signals at 16.7 °2 ⁇ , 13.7 °2 ⁇ , 14.9 °2 ⁇ , 17.1 °2 ⁇ , and 17.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 2 is crystalline DOM maleate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.7 °2 ⁇ . 13.7 °2 ⁇ , 14.9 °2 ⁇ , 17.1 °2 ⁇ , 17.8 °2 ⁇ , and 28.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM maleate Form 2 is crystalline DOM maleate Form 2 characterized by XRPD signals at 16.7 °2 ⁇ , 13.7 °2 ⁇ , 14.9 °2 ⁇ , 17. 1 °2 ⁇ , 17.8 °2 ⁇ , and 28.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM maleate Form 2 is characterized by one, two, three, four, five, or six XRPD signals selected from those set forth in Table 16A.
  • the present disclosure provides solid forms of DOM malonate Form 1, e.g., crystalline forms of DOM malonate Form 1 .
  • the DOM malonate Form 1 XRPD profile is substantially similar to that shown in FIGs. 13 or 66.
  • the DOM malonate Form 1 NMR spectrum is substantially similar to that shown in FIG. 46.
  • the DOM malonate Form 1 TGA profile is substantially similar to that shown in FIG. 47.
  • the DOM malonate Form 1 DSC profile is substantially similar to that shown in FIG. 47.
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ . 16.3 °2 ⁇ , and 17.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 16.3 °2 ⁇ , and 17.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is ay stall ine DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 15.7 °2 ⁇ , 16.3 °2 ⁇ , 17.2 °2 ⁇ , and 21.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 15.7 °2 ⁇ , 16.3 °2 ⁇ ,
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 25.5 °2 ⁇ , and 21.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 25.5 °2 ⁇ , and 21.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 25.5 °2 ⁇ , 21.2 °2 ⁇ , 26.1 °2 ⁇ , and 22.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is DOM malonate Form 1 characterized by XRPD signals at 12,6 °2 ⁇ , 25.5 °2 ⁇ , 21.2 °2 ⁇ , 26.1 °2 ⁇ , and 22,4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 25.5 °2 ⁇ , 21,2 °2 ⁇ , 26.1 °2 ⁇ , 22.4 °2 ⁇ , 16.3 °2 ⁇ , and 14.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is DOM malonate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 25.5 °2 ⁇ ,
  • the solid form of DOM malonate Form 1 is ay stall ine DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 25.5 °2 ⁇ , 21.2 °2 ⁇ , 26.1 °2 ⁇ , 22.4 °2 ⁇ , 16.3 °2 ⁇ , 14.2 °2 ⁇ , 15.2 °2 ⁇ , 22.8 °2 ⁇ , and 24.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is DOM malonate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 25.5 °2 ⁇ , 21.2 °2 ⁇ , 26.1 °2 ⁇ , 22.4 °2 ⁇ , 16.3 °2 ⁇ , 14.2 °2 ⁇ , 15.2 °2 ⁇ , 22.8 °2 ⁇ , and 24.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM malonate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one XRPD signals selected from those set forth in Table 17.
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 15.6 °2 ⁇ , 16.3 °2 ⁇ , 17.2 °2 ⁇ , and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 15.6 °2 ⁇ , 16.3 °2 ⁇ , 17.2 °2 ⁇ , and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.4 °2 ⁇ , 16.3 °2 ⁇ , and 4.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ , or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form I is crystalline DOM malonate Form 1 characterized by XRPD signals at 22.4 °2 ⁇ , 16.3 °2 ⁇ , and 4.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.4 °2 ⁇ , 16.3 °2 ⁇ , 4.2 °2 ⁇ , 26.1 °2 ⁇ , and 26.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is DOM malonate Form 1 characterized by XRPD signals at 22.4 °2 ⁇ , 16.3 °2 ⁇ , 4.2 °2 ⁇ , 26.1 °2 ⁇ , and 26.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.4 °2 ⁇ , 16.3 °2 ⁇ , 4.2 °2 ⁇ , 26.1 °2 ⁇ , 26.0 °2 ⁇ , 4.7 °2 ⁇ , and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is DOM malonate Form 1 characterized by XRPD signals at 22.4 °2 ⁇ , 16.3 °2 ⁇ , 4.2 °2 ⁇ , 26.1 °2 ⁇ , 26.0 °2 ⁇ , 4.7 °2 ⁇ , and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is crystalline DOM malonate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 22.4 °2 ⁇ , 16.3 °2 ⁇ , 4.2 °2 ⁇ , 26.1 °2 ⁇ , 26.0 °2 ⁇ , 4.7 °2 ⁇ , 21.1 °2 ⁇ , 22,7 °2 ⁇ , 25.4 °2 ⁇ , and 15.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 1 is DOM malonate Form 1 characterized by XRPD signals at 22.4 °2 ⁇ , 16.3 °2 ⁇ , 4.2 °2 ⁇ , 26.1 °2 ⁇ , 26.0 °2 ⁇ , 4.7 °2 ⁇ , 21.1 °2 ⁇ , 22.7 °2 ⁇ , 25.4 °2 ⁇ , and 15.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM malonate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, or forty-four XRPD signals selected from those set forth in Table 18.
  • the present disclosure provides solid forms of DOM malonate Form 2, e.g., crystalline forms of DOM malonate Form 2.
  • the DOM malonate Form 2 XRPD profile is substantially similar to that shown in FIG. 67.
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 11.8 °2 ⁇ , and 13.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by XRPD signals at 6.0 °2 ⁇ , 11.8 °2 ⁇ , and 13.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6,0 °2 ⁇ , 1 1.8 °2 ⁇ , 13.4 °2 ⁇ , 15.8 °2 ⁇ , and 16.5 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by XRPD signals at 6.0 °2 ⁇ , 11.8 °2 ⁇ , 13.4 °2 ⁇ , 15.8 °2 ⁇ , and 16,5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 15.8 °2 ⁇ , and 18.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ , or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by XRPD signals at 6.0 °2 ⁇ , 15.8 °2 ⁇ , and 18.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 15.8 °2 ⁇ , 18.8 °2 ⁇ , 16.5 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is DOM malonate Form 2 characterized by XRPD signals at 6.0 °2 ⁇ , 15.8 °2 ⁇ , 18.8 °2 ⁇ , 16.5 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 15.8 °2 ⁇ , 18.8 °2 ⁇ , 16.5 °2 ⁇ , 22.0 °2 ⁇ , 13.4 °2 ⁇ , and 22.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is DOM malonate Form 2 characterized by XRPD signals at 6.0 °2 ⁇ , 15.8 °2 ⁇ , 18.8 °2 ⁇ , 16.5 °2 ⁇ , 22.0 °2 ⁇ , 13.4 °2 ⁇ , and 22.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or .0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is crystalline DOM malonate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 15.8 °2 ⁇ , 18.8 °2 ⁇ , 16.5 °2 ⁇ , 22.0 °2 ⁇ , 13.4 °2 ⁇ , 22.7 °2 ⁇ , 24.7 °2 ⁇ , 20.1 °2 ⁇ , and. 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM malonate Form 2 is DOM malonate Form 2 characterized by XRPD signals at 6.0 °2 ⁇ , 15.8 °2 ⁇ , 18.8 °2 ⁇ , 16.5 °2 ⁇ , 22.0 °2 ⁇ , 13.4 °2 ⁇ , 22.7 °2 ⁇ , 24.7 °2 ⁇ , 20.1 °2 ⁇ , and 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM malonate Form 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty 7 , twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, or thirty-six XRPD signals selected from those set forth in Table 19.
  • the present disclosure provides solid, forms of DOM mesylate, e.g., crystalline forms of DOM mesylate.
  • the DOM mesylate XRPD profile is substantially similar to that shown in FIG. 14.
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.9 °2 ⁇ , 16.3 °2 ⁇ , and 17.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized by XRPD signals at 12.9 °2 ⁇ , 16.3 °2 ⁇ , and 17.0 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.9 20. 14.9 °2 ⁇ , 16.3 °2 ⁇ , 17.0 °2 ⁇ . and 22.6 °2 ⁇ ( ⁇ 0.2 20: ⁇ 0.1 20: or ⁇ 0.0 °2 ⁇ , Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized by XRPD signals at 12.9 °2 ⁇ , 14.9 °2 ⁇ , 16.3 °2 ⁇ , 17.0 °2 ⁇ , and 22.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesy late characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.0 °2 ⁇ , 16.3 °2 ⁇ , and 4. 1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized, by XRPD signals at 17.0 °2 ⁇ , 16.3 °2 ⁇ , and 4.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.0 °2 ⁇ , 16.3 °2 ⁇ , 4.1 °2 ⁇ , 3.9 °2 ⁇ , and 24.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 29; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is DOM mesylate characterized by XRPD signals at 17.0 °2 ⁇ , 16.3 °2 ⁇ , 4.1 °2 ⁇ , 3.9 °2 ⁇ , and 24.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.0 °2 ⁇ , 16.3 °2 ⁇ , 4. 1 °2 ⁇ , 3.9 °2 ⁇ , 24,0 °2 ⁇ , 23/1 °2 ⁇ , and 25.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is DOM mesylate characterized by XRPD signals at 17.0 °2 ⁇ , 16.3 °2 ⁇ , 4.1 °2 ⁇ , 3.9 °2 ⁇ , 24.0 °2 ⁇ , 23.4 °2 ⁇ , and 25.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 : 29. Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is crystalline DOM mesylate characterized by two or more, or three or more XRPD signals selected from the group consisting of 17.0 °2 ⁇ , 16.3 °2 ⁇ , 4.1 °2 ⁇ , 3.9 °2 ⁇ , 24.0 °2 ⁇ , 23.4 °2 ⁇ , 25.5 °2 ⁇ , 22.6 °2 ⁇ , 22.0 °2 ⁇ , and 21.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mesylate is DOM mesylate characterized by XRPD signals at 17.0 °2 ⁇ , 16.3 °2 ⁇ , 4.1 °2 ⁇ , 3.9 °2 ⁇ , 24.0 °2 ⁇ , 23.4 °2 ⁇ , 25.5 °2 ⁇ , 22.6 °2 ⁇ , 22.0 °2 ⁇ , and 21.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM mesylate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, or forty-four XRPD signals selected from those set forth in Table 20.
  • the present disclosure provides solid forms of DOM mucate, e.g., crystalline forms of DOM mucate.
  • the DOM mucate XRPD profile is substantially similar to that shown in FIG. 21.
  • the DOM mucate 1 H NMR spectrum is substantially similar to that shown in FIG. 48.
  • the DOM mucate TGA profile is substantially similar to that shown in FIG. 49.
  • the DOM mucate DSC profile is substantially similar to that shown in FIG. 49.
  • the solid form of DOM mucate is crystalline DOM mucate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.6 °2 ⁇ , 9.2 °2 ⁇ , and 13.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is crystalline DOM mucate characterized, by XRPD signals at 4.6 °2 ⁇ , 9.2 °2 ⁇ , and 13.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is crystalline DOM mucate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.6 °2 ⁇ , 9.2 °2 ⁇ , 13.2 °2 ⁇ , 13,8 °2 ⁇ , and 16.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is crystalline DOM mucate characterized by XRPD signals at 4.6 °2 ⁇ , 9.2 °2 ⁇ , 13.2 °2 ⁇ , 13.8 °2 ⁇ , and 16. 1 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is crystalline DOM mucate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.6 °2 ⁇ , 13.8 °2 ⁇ , 9.2 °2 ⁇ , 25.4 °2 ⁇ , and 16.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is DOM mucate characterized by XRPD signals at 4.6 °2 ⁇ , 13.8 °2 ⁇ , 9.2 °2 ⁇ , 25.4 °2 ⁇ , and 16.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is crystalline DOM mucate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.6 °2 ⁇ , 13.8 °2 ⁇ , 9.2 °2 ⁇ , 25.4 °2 ⁇ , 16.6 °2 ⁇ , 18.1 °2 ⁇ , and 21.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is DOM mucate characterized by XRPD signals at 4.6 °2 ⁇ , 13.8 °2 ⁇ , 9.2 °2 ⁇ , 25.4 °2 ⁇ , 16.6 °2 ⁇ , 18.1 °2 ⁇ , and 21.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is crystalline DOM mucate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.6 °2 ⁇ , 13.8 °2 ⁇ , 9.2 °2 ⁇ , 25.4 °2 ⁇ , 16.6 °2 ⁇ , 18.1 °2 ⁇ , 21.0 °2 ⁇ , 16.1 °2 ⁇ , 13.2 °2 ⁇ , and 23.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM mucate is DOM mucate characterized by XRPD signals at 4.6 °2 ⁇ , 13.8 °2 ⁇ , 9.2 °2 ⁇ , 25.4 °2 ⁇ , 16.6 °2 ⁇ , 18.1 °2 ⁇ , 21.0 °2 ⁇ , 16.1 °2 ⁇ , 13.2 °2 ⁇ , and 23.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM mucate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, or twenty-eight XRPD signals selected from those set forth in Table 21.
  • the present disclosure provides solid forms of DOM phosphate, e.g., crystalline forms of DOM phosphate.
  • the DOM phosphate XRPD profile is substantially similar to that shown in FIGs. 16 or 68
  • the DOM phosphate NMR spectrum is substantially similar to that shown in FIG. 50
  • the DOM phosphate TGA profile is substantially similar to that shown in FIG. 51.
  • the DOM phosphate DSC profile is substantially similar to that shown in FIG. 51.
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 8.1 °2 ⁇ , and 12.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ . 8.1 °2 ⁇ , and 12.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 8.1 °2 ⁇ . 12.2 °2 ⁇ , 16.7 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ . Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 8.1 °2 ⁇ , 12.2 °2 ⁇ , 16.7 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 12.2 °2 ⁇ , and 24.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 12.2 °2 ⁇ , and 24.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 12.2 °2 ⁇ , 24.5 °2 ⁇ , 16.7 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 12.2 °2 ⁇ , 24.5 °2 ⁇ , 16.7 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 12.2 °2 ⁇ , 24.5 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 23.0 °2 ⁇ , and 25.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 12,2 °2 ⁇ , 24.5 °2 ⁇ , 16.7 °2 ⁇ , 22,0 °2 ⁇ , 23.0 °2 ⁇ , and 25/4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 12.2 °2 ⁇ , 24.5 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 23.0 °2 ⁇ , 25.4 °2 ⁇ , 21.5 °2 ⁇ , 8.1 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 12.2 °2 ⁇ , 24.5 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 23.0 °2 ⁇ , 25.4 °2 ⁇ , 21.5 °2 ⁇ , 8.1 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM phosphate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, or twenty-seven XRPD signals selected from those set forth in Table 22. Table 22. XRPD Signals for DOM phosphate
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 16.7 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 16.7 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is cry stalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 24.6 °2 ⁇ , and 12.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 24.6 °2 ⁇ , and 12.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is cry stalline DOM phosphate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.1 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 24.6 °2 ⁇ , 12.2 °2 ⁇ , 23.0 °2 ⁇ , and 25.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 24.6 °2 ⁇ , 12.2 °2 ⁇ , 23.0 °2 ⁇ , and 25.4 °2 ⁇ (. ⁇ 0.2 °2 ⁇ ; . ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is crystalline DOM phosphate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 4.1 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 24.6 °2 ⁇ , 12.2 °2 ⁇ , 23.0 °2 ⁇ , 25.4 °2 ⁇ , 21.5 °2 ⁇ , 20.8 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM phosphate is DOM phosphate characterized by XRPD signals at 4.1 °2 ⁇ , 16.7 °2 ⁇ , 22.0 °2 ⁇ , 24.6 °2 ⁇ , 12.2 °2 ⁇ , 23.0 °2 ⁇ , 25.4 °2 ⁇ , 21.5 °2 ⁇ , 20.8 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 26: or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM phosphate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, or forty XRPD signals selected from those set forth in Table 23.
  • the present disclosure provides solid forms of DOM sulfate, e.g., crystalline forms of DOM sulfate.
  • the DOM sulfate XRPD profile is substantially similar to that shown in FIGs. 17 or 69.
  • the DOM sulfate 1 H NMR spectrum is substantially similar to that shown in FIG. 54.
  • the DOM sulfate TGA profile is substantially similar to that shown in FIG. 55.
  • the DOM sulfate DSC profile is substantially similar to that shown in FIG. 55.
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °2 ⁇ , 13.8 °2 ⁇ , and 20.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by XRPD signals at 11.2 °2 ⁇ , 13.8 °2 ⁇ , and 20.4 °2 ⁇ (. ⁇ 0.2 °2 ⁇ ; . ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °2 ⁇ , 13.8 °2 ⁇ , 17.3 °2 ⁇ , 20.4 °2 ⁇ , and 20.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is cry stalline DOM sulfate characterized by XRPD signals at 11.2 °2 ⁇ , 13.8 °2 ⁇ , 17.3 °2 ⁇ , 20.4 °2 ⁇ , and 20.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 20.4 °2 ⁇ , 13.8 °2 ⁇ , and 20.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by XRPD signals at 20,4 °2 ⁇ , 13.8 °2 ⁇ , and 20.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.4 °2 ⁇ , 13.8 °2 ⁇ , 20.8 °2 ⁇ , 24/4 °2 ⁇ , and 25.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is DOM sulfate characterized by XRPD signals at 20.4 °2 ⁇ , 13.8 °2 ⁇ , 20.8 °2 ⁇ , 24.4 °2 ⁇ , and 25. 1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.4 °2 ⁇ , 13.8 °2 ⁇ , 20.8 °2 ⁇ , 24.4 °2 ⁇ , 25.1 °2 ⁇ , 1 1.2 °2 ⁇ , and 24.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ , or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is DOM sulfate characterized by XRPD signals at 20.4 °2 ⁇ , 13.8 °2 ⁇ , 20.8 °2 ⁇ , 24.4 °2 ⁇ , 25. 1 °2 ⁇ , 11.2 °2 ⁇ , and 24.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.4 °2 ⁇ , 13.8 °2 ⁇ , 20.8 °2 ⁇ , 24.4 °2 ⁇ , 25.1 °2 ⁇ , 11.2 °2 ⁇ , 24.1 °2 ⁇ , 20.2 °2 ⁇ , 17.3 °2 ⁇ , and 23.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is DOM sulfate characterized by XRPD signals at 20.4 °2 ⁇ , 13.8 °2 ⁇ , 20.8 °2 ⁇ , 24.4 °2 ⁇ , 25.1 °2 ⁇ , 11.2 °2 ⁇ , 24. 1 20. 20 2 ; °2 ⁇ . 1'7.3 °2 ⁇ , and 23.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM sulfate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, or thirty-one XRPD signals selected from those set forth in Table 24.
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.1 °2 ⁇ , 13.6 °2 ⁇ , and 14.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by XRPD signals at 5.1 °2 ⁇ , 13,6 °2 ⁇ , and 14.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.1 °2 ⁇ , 10.4 °2 ⁇ , 13.6 °2 ⁇ , 14.7 °2 ⁇ , and 20.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by XRPD signals at 5.1 °2 ⁇ , 10.4 °2 ⁇ , 13.6 °2 ⁇ , 14.7 °2 ⁇ , and 20.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.4 °2 ⁇ , 24.4 °2 ⁇ , and 14.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by XRPD signals at 20.4 °2 ⁇ , 24.4 °2 ⁇ , and 14.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.4 °2 ⁇ , 24.4 °2 ⁇ , 14.7 °2 ⁇ , 5.1 °2 ⁇ , and 13.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is DOM sulfate characterized by XRPD signals at 20.4 °2 ⁇ , 24.4 °2 ⁇ , 14.7 °2 ⁇ , 5.1 °2 ⁇ , and 13.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 20.4 °2 ⁇ , 24.4 °2 ⁇ , 14.7 °2 ⁇ , 5.1 °2 ⁇ , 13.6 °2 ⁇ , 25.1 °2 ⁇ , and 10.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is DOM sulfate characterized by XRPD signals at 20.4 °2 ⁇ , 24.4 °2 ⁇ , 14.7 °2 ⁇ , 5.1 °2 ⁇ , 13.6 °2 ⁇ , 25.1 °2 ⁇ , and. 10.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is crystalline DOM sulfate characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.4 °2 ⁇ , 24.4 °2 ⁇ , 14.7 °2 ⁇ , 5.1 °2 ⁇ , 13.6 °2 ⁇ , 25.1 °2 ⁇ , 10.4 °2 ⁇ , 17.1 °2 ⁇ , 20.8 °2 ⁇ , and 23.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM sulfate is DOM sulfate characterized by XRPD signals at 20.4 °2 ⁇ , 24.4 °2 ⁇ , 14.7 °2 ⁇ , 5.1 °2 ⁇ , 13.6 °2 ⁇ , 25.1 °2 ⁇ , 10.4 °2 ⁇ , 17.1 °2 ⁇ , 20.8 °2 ⁇ , and 23.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ : ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM sulfate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, or forty XRPD signals selected from those set forth in Table 25.
  • the present disclosure provides solid forms of DOM succinate, e.g., crystalline forms of DOM succinate.
  • the DOM succinate XRPD profile is substantially similar to that shown in FIG. 18.
  • the DOM succinate 1 H NMR spectrum is substantially similar to that shown in FIG. 52.
  • the DOM succinate TGA profile is substantially similar to that shown in FIG. 53.
  • the DOM succinate DSC profile is substantially similar to that shown in FIG. 53.
  • the solid form of DOM succinate is crystalline DOM succinate characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.8 °2 ⁇ , 9.6 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by XRPD signals at 4.8 °2 ⁇ , 9.6 26. and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 4.8 °2 ⁇ , 9.6 °2 ⁇ , 10.6 °2 ⁇ , 14.4 °2 ⁇ , and 19.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by XRPD signals at 4.8 °2 ⁇ , 9.6 °2 ⁇ , 10.6 °2 ⁇ , 14.4 °2 ⁇ , and 19.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °2 ⁇ , 4.8 °2 ⁇ , and 14.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by XRPD signals at 9.6 °2 ⁇ . 4.8 °2 ⁇ , and 14.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °2 ⁇ , 4.8 °2 ⁇ , 14.4 °2 ⁇ , 19.2 °2 ⁇ , and 21.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is DOM succinate characterized by XRPD signals at 9.6 °2 ⁇ , 4.8 °2 ⁇ , 14.4 °2 ⁇ , 19.2 °2 ⁇ , and 21.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °2 ⁇ , 4.8 °2 ⁇ , 14.4 °2 ⁇ , 19.2 °2 ⁇ , 21.4 °2 ⁇ , 25.0 °2 ⁇ , and 24.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is DOM succinate characterized by XRPD signals at 9.6 °2 ⁇ , 4.8 °2 ⁇ , 14.4 °2 ⁇ , 19.2 °2 ⁇ , 21,4 °2 ⁇ , 25.0 °2 ⁇ , and 24.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is crystalline DOM succinate characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °2 ⁇ , 4.8 °2 ⁇ , 14.4 °2 ⁇ , 19.2 °2 ⁇ , 21.4 °2 ⁇ , 25.0 °2 ⁇ , 24.0 °2 ⁇ , 10.6 °2 ⁇ , 27.7 °2 ⁇ , and 18.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM succinate is DOM succinate characterized by XRPD signals at 9.6 °2 ⁇ , 4.8 °2 ⁇ , 14.4 °2 ⁇ , 19.2 °2 ⁇ , 21.4 °2 ⁇ , 25.0 °2 ⁇ , 24.0 °2 ⁇ , 10.6 °2 ⁇ , 27.7 °2 ⁇ , and 18.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM succinate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, or twenty-five XRPD signals selected from those set forth in Table 26. Table 26. XRPD Signals for DOM succinate
  • the present disclosure provides solid, forms of DOM L-tartrate, e.g., crystalline forms of DOM L-tartrate Form 1.
  • the DOM L-tartrate Form 1 XRPD profile is substantially similar to that shown in FIGs. 19 or 70
  • the DOM L-tartrate Form 1 1 H NMR spectrum is substantially similar to that shown in FIG. 56.
  • the DOM L-tartrate Form 1 TGA profile is substantially similar to that shown in FIG, 57.
  • the DOM L-tartrate DSC Form 1 profile is substantially similar to that shown in FIG. 57.
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.1 °2 ⁇ , 10.6 °2 ⁇ , and 12.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by XRPD signals at 6.1 °2 ⁇ , 10.6 °2 ⁇ , and 12.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.1 °2 ⁇ , 10.6 °2 ⁇ , 12.2 °2 ⁇ , 18.4 °2 ⁇ , and 20.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L-tartrate Form 1 characterized by XRPD signals at 6.1 °2 ⁇ , 10.6 °2 ⁇ , 12.2 °2 ⁇ , 18.4 °2 ⁇ , and. 20.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.2 °2 ⁇ , 18.4 °2 ⁇ , and 13.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L ⁇ tartrate Form 1 characterized by XRPD signals at 12.2 °2 ⁇ , 18.4 °2 ⁇ , and 13.7 °2 ⁇ ( ⁇ 0.2. °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.2 °2 ⁇ , 18.4 °2 ⁇ , 13.7 °2 ⁇ , 21.0 °2 ⁇ , and 13.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is DOM L-tartrate Form 1 characterized by XRPD signals at 12.2 °2 ⁇ , 18.4 °2 ⁇ , .13.7 °2 ⁇ , 21.0 °2 ⁇ , and 13,5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- ta.rt.rate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.2 °2 ⁇ , 18.4 °2 ⁇ , 13.7 °2 ⁇ , 21.0 °2 ⁇ , 13.5 °2 ⁇ , 20.2 °2 ⁇ , and 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L- tartrate Form 1 is DOM L-tartrate Form 1 characterized by XRPD signals at 1.2.2 °2 ⁇ , 18.4 °2 ⁇ , 13.7 °2 ⁇ , 21.0 °2 ⁇ , 13.5 °2 ⁇ , 20.2 °2 ⁇ , and 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.2 °2 ⁇ , 18.4 °2 ⁇ , 13.7 °2 ⁇ , 21.0 °2 ⁇ , 13.5 °2 ⁇ , 20.2 °2 ⁇ , 23.9 °2 ⁇ , 6.1 °2 ⁇ , 27.2 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is DOM L-tartrate Form 1 characterized by XRPD signals at 12.2 °2 ⁇ , 18.4 °2 ⁇ , 13.7 °2 ⁇ , 21.0 °2 ⁇ , 13.5 °2 ⁇ , 20.2 °2 ⁇ , 23.9 °2 ⁇ , 6.1 °2 ⁇ , 27.2 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM L-tartrate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, or thirty-four XRPD signals selected from those set forth in Table 27.
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 12.1 °2 ⁇ , and 18.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L ⁇ tartrate Form 1 characterized by XRPD signals at 6.0 °2 ⁇ , 12.1 °2 ⁇ , and 18.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 12.1 °2 ⁇ , 13.6 °2 ⁇ , 18.2 °2 ⁇ , and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L-tartrate Form 1 characterized by XRPD signals at 6.0 °2 ⁇ , 12, 1 °2 ⁇ , 13.6 °2 ⁇ , 18.2 °2 ⁇ , and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- ta.rt.rate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12. 1 °2 ⁇ , 18.2 °2 ⁇ , and 13.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by XRPD signals at 12.1 °2 ⁇ , 18.2 °2 ⁇ , and 13.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12. 1 °2 ⁇ , 18.2 °2 ⁇ , 13.6 °2 ⁇ , 21.1 °2 ⁇ , and 20.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is DOM L-tartrate Form 1 characterized by XRPD signals at 12.1 °2 ⁇ .
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.1 °2 ⁇ , 18.2 °2 ⁇ , 13.6 °2 ⁇ , 21.1 °2 ⁇ , 20.2 °2 ⁇ , 6.0 °2 ⁇ , and 23.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L- tartrate Form 1 is DOM L-tartrate Form 1 characterized by XRPD signals at 12.1 °2 ⁇ , 18.2 °2 ⁇ , 13.6 °2 ⁇ , 21. 1 °2 ⁇ , 20.2 °2 ⁇ , 6.0 °2 ⁇ , and 23.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ : ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is crystalline DOM L- tartrate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.1 °2 ⁇ , 18.2 °2 ⁇ , 13.6 °2 ⁇ , 21.1 °2 ⁇ , 20.2 °2 ⁇ , 6.0 °2 ⁇ , 23.6 °2 ⁇ , 2.7.2 °2 ⁇ , 29.3 °2 ⁇ , and 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-tartrate Form 1 is DOM L-tartrate Form 1 characterized by XRPD signals at 12.1 °2 ⁇ , 18.2 °2 ⁇ , 13.6 °2 ⁇ , 21.1 °2 ⁇ , 2.0.2 °2 ⁇ , 6.0 °2 ⁇ , 23.6 °2 ⁇ , 27.2 °2 ⁇ , 29.3 °2 ⁇ , and. 10.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM L-tartrate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty’, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, or twenty-eight XRPD signals selected from those set forth in Table 28.
  • the present disclosure provides solid, forms of DOM tosylate Form 1, e.g., crystalline forms of DOM tosylate Form 1.
  • the DOM tosylate Form 1 XRPD profile is substantially similar to that shown in FIG. 20.
  • the DOM tosylate Form 1 l H NMR spectrum is substantially similar to that shown in FIG. 58.
  • the DOM tosylate Form 1 TGA profile is substantially similar to that shown in FIG. 59.
  • the DOM tosylate Form 1 DSC profile is substantially similar to that shown in FIG, 59,
  • the solid form of DOM tosylate Form 1 is crystalline DOM tosylate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 7.7 °2 ⁇ , and 11.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0. 1 °2 ⁇ , or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 1 is crystalline DOM tosylate Form 1 characterized by XRPD signals at 6.0 °2 ⁇ , 7.7 °2 ⁇ , and 11.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 1 is crystalline DOM tosylate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 6.0 °2 ⁇ , 7.7 °2 ⁇ , 8.4 °2 ⁇ , 10.3 °2 ⁇ , and 1 1.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM tosylate Form 1 is cry stalline DOM tosylate Form 1 characterized by XRPD signals at 6.0 °2 ⁇ , 7.7 °2 ⁇ , 8.4 °2 ⁇ , 10.3 °2 ⁇ , and 11.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 1 is crystalline DOM tosylate Form 1 characterized by two or more, or three or more XR PD signals selected from the group consisting of 11.9 °2 ⁇ , 6.0 °2 ⁇ , 7.7 °2 ⁇ . 22.0 : 29. and 8.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM tosylate Form 1 is DOM tosylate Form 1 characterized by XRPD signals at 11.9 °2 ⁇ , 6.0 °2 ⁇ , 7.7 °2 ⁇ , 22.0 °2 ⁇ , and 8.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 1 is crystalline DOM tosylate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.9 °2 ⁇ , 6.0 °2 ⁇ , 7.7 °2 ⁇ , 22.0 °2 ⁇ , 8.4 °2 ⁇ , 24.7 °2 ⁇ , and. 23.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 1 is DOM tosylate Form 1 characterized by XRPD signals at 11.9 °2 ⁇ , 6.0 °2 ⁇ , 7.7 °2 ⁇ , 22.0 °2 ⁇ , 8.4 °2 ⁇ , 24.7 °2 ⁇ , and 23.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 1 is crystalline DOM tosylate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.9 °2 ⁇ , 6.0 °2 ⁇ , 7.7 °2 ⁇ , 22.0 °2 ⁇ , 8.4 °2 ⁇ , 24.7 °2 ⁇ , 23.4 °2 ⁇ , 22.8 °2 ⁇ , 21.5 °2 ⁇ , and 19,7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 1 is DOM tosylate Form 1 characterized by XRPD signals at 11,9 °2 ⁇ , 6.0 °2 ⁇ , 7.7 °2 ⁇ , 22.0 °2 ⁇ , 8.4 °2 ⁇ , 24.7 °2 ⁇ , 23.4 °2 ⁇ , 22.8 °2 ⁇ , 21.5 °2 ⁇ , and 19.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM tosylate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, or forty-eight XRPD signals selected from those set forth in Table 29.
  • the present disclosure provides solid forms of DOM tosylate Form 2, e.g., crystalline forms of DOM tosylate Form 2.
  • the DOM tosylate Form 2 XRPD profile is substantially similar to that shown in FIG. 71.
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.8 °2 ⁇ , 7.9 °2 ⁇ , and 11.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0. 1 °2 ⁇ , or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by XRPD signals at 5.8 °2 ⁇ , 7.9 °2 ⁇ , and 11.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.8 °2 ⁇ . 7.9 °2 ⁇ , 11.7 °2 ⁇ , 14.2 °2 ⁇ , and 22.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by XRPD signals at 5.8 °2 ⁇ , 7.9 °2 ⁇ , 11.7 °2 ⁇ , 14.2 °2 ⁇ , and 22.3 °2 ⁇ ( ⁇ 0.2 : 29: ⁇ 0.1 : 29: or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °2 ⁇ , 22.3 °2 ⁇ , and 5.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by XRPD signals at 11.7 °2 ⁇ , 22.3 °2 ⁇ , and 5.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.7 °2 ⁇ , 22.3 °2 ⁇ , 5.8 °2 ⁇ , 7.9 °2 ⁇ , and 19.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is DOM tosylate Form 2 characterized by XRPD signals at 11.7 °2 ⁇ , 22.3 °2 ⁇ , 5.8 °2 ⁇ , 7.9 °2 ⁇ , and 19.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 1 1.7 °2 ⁇ , 22.3 °2 ⁇ , 5.8 °2 ⁇ , 7.9 °2 ⁇ , 19.2 °2 ⁇ , 18.6 °2 ⁇ , and 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is DOM tosylate Form 2 characterized by XRPD signals at 11.7 °2 ⁇ , 22.3 °2 ⁇ , 5.8 °2 ⁇ , 7.9 °2 ⁇ ,
  • the solid form of DOM tosylate Form 2 is crystalline DOM tosylate Form 2 characterized by two or more, or three or more XR PD signals selected from the group consisting of 11.7 °2 ⁇ , 22.3 °2 ⁇ , 5.8 °2 ⁇ , 7.9 °2 ⁇ , 19.2 °2 ⁇ , 18.6 °2 ⁇ , 23.9 °2 ⁇ , 23.6 °2 ⁇ , 21.8 °2 ⁇ , and 20.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM tosylate Form 2 is DOM tosylate Form 2 characterized by XRPD signals 11.7 °2 ⁇ ,
  • the crystalline DOM tosylate Form 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, or thirty-one XRPD signals selected from those set forth in Table 30.
  • the present disclosure provides solid forms of DOM ethanesulfonate (esylate), e.g., crystalline forms of DOM ethanesulfonate.
  • the DOM ethanesulfonate XRPD profile is substantially similar to that shown in FIG. 22.
  • the DOM ethanesulfonate 1 H NMR spectrum is substantially similar to that shown in FIG, 28.
  • the DOM ethanesulfonate TGA profile is substantially similar to that shown in FIG. 29.
  • the DOM ethanesulfonate DSC profile is substantially similar to that shown in FIG. 29.
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 7.6 °2 ⁇ , 13.0 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ . or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by XRPD signals at 7.6 °2 ⁇ , 13.0 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 7.6 °2 ⁇ , 13.0 °2 ⁇ , 15.1 °2 ⁇ , 20.0 °2 ⁇ , and 22.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by XRPD signals at 7.6 °2 ⁇ , 13.0 °2 ⁇ , 15.1 °2 ⁇ , 20.0 °2 ⁇ , and 22.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 7.6 °2 ⁇ . 22.8 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by XRPD signals at 7.6 °2 ⁇ , 22.8 °2 ⁇ , and 15.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 7.6 °2 ⁇ , 22.8 29. 15.1 °2 ⁇ , 13.0 26. 20.0 °2 ⁇ , 13.3 °2 ⁇ , and 22.0 26 ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is DOM ethanesulfonate characterized by XRPD signals at 7.6 °2 ⁇ , 22.8 °2 ⁇ , 15.1 °2 ⁇ , 13.0 °2 ⁇ , 20.0 °2 ⁇ , 13.3 °2 ⁇ , and 22.0 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is crystalline DOM ethanesulfonate characterized by two or more, or three or more XRPD signals selected from the group consisting of 7,6 °2 ⁇ , 22.8 °2 ⁇ , 15.1 °2 ⁇ , 13.0 °2 ⁇ , 20.0 °2 ⁇ , 13.3 °2 ⁇ , 22.0 °2 ⁇ , 19,8 °2 ⁇ , 17.1 °2 ⁇ , and 9.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM ethanesulfonate is DOM ethanesulfonate characterized by XRPD signals at 7.6 °2 ⁇ , 22.8 °2 ⁇ , 15.1. °2 ⁇ , 13.0 °2 ⁇ , 20.0 °2 ⁇ , 13.3 °2 ⁇ , 22.0 °2 ⁇ , 19.8 °2 ⁇ , 17.1 °2 ⁇ , and 9.9 °2 ⁇ ( ⁇ 0,2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM ethanesulfonate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, or twenty-eight XRPD signals selected from those set forth in Table 31 .
  • the present disclosure provides solid forms of DOM lactate, e.g., crystalline forms of DOM lactate.
  • the DOM lactate XRPD profile is substantially similar to that shown in FIG. 23.
  • the DOM lactate *H NMR spectrum is substantially similar to that shown in FIG. 40.
  • the DOM lactate TGA profile is substantially similar to that shown in FIG. 41.
  • the DOM lactate DSC profile is substantially similar to that shown in FIG. 41.
  • the solid form of DOM lactate is crystalline DOM lactate characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.3 °2 ⁇ , 12.5 °2 ⁇ , and 13.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is crystalline DOM lactate characterized by XRPD signals at 10.3 °2 ⁇ , 12.5 °2 ⁇ , and 13.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM lacta te is crystalline DOM lactate characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.3 °2 ⁇ , 12.5 °2 ⁇ , 13.1 °2 ⁇ , 14.6 °2 ⁇ , and 16.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is crystalline DOM lactate characterized by XRPD signals at 10.3 °2 ⁇ , 12.5 °2 ⁇ , 13.1 °2 ⁇ , 14.6 °2 ⁇ , and 16.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is crystalline DOM lactate characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.3 °2 ⁇ , 21.6 °2 ⁇ , and 16.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is crystalline DOM lactate characterized by XRPD signals at 25.3 °2 ⁇ , 21.6 °2 ⁇ , and 16.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is crystalline DOM lactate characterized by two or more, or three or more XRPD signals selected, from the group consisting of 25.3 °2 ⁇ , 21.6 °2 ⁇ , 16.2 °2 ⁇ , 13.1 °2 ⁇ , and 14.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is DOM lactate characterized by XRPD signals at 25.3 °2 ⁇ , 21.6 °2 ⁇ , 1.6.2 °2 ⁇ , .13.1 °2 ⁇ , and 14.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1. radiation).
  • the solid form of DOM lactate is crystalline DOM lactate characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.3 °2 ⁇ , 21.6 °2 ⁇ , 16.2 °2 ⁇ , 13.1 °2 ⁇ , 14.6 °2 ⁇ , 17.8 °2 ⁇ , and 17.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is DOM lactate characterized by XRPD signals at 25.3 °2 ⁇ , 21.6 °2 ⁇ , 16.2 °2 ⁇ , 13.1 °2 ⁇ , 14.6 °2 ⁇ , 17.8 : 29. and 17.7 °2 ⁇ ( ⁇ 0.2 20: ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ , Cu K ⁇ 1 radiation).
  • the solid form of DOM lacta te is crystalline DOM lactate characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.3 °2 ⁇ , 21.6 °2 ⁇ , 16.2 °2 ⁇ , 13.1 °2 ⁇ , 14.6 °2 ⁇ , 17.8 °2 ⁇ , 17.7 °2 ⁇ , 12.5 °2 ⁇ , 26.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM lactate is DOM lactate characterized by XRPD signals at 25.3 °2 ⁇ , 21.6 °2 ⁇ , 16.2 °2 ⁇ , 13.1 °2 ⁇ , 14.6 °2 ⁇ , 17.8 °2 ⁇ , 17.7 °2 ⁇ , 12.5 °2 ⁇ , 26.2 °2 ⁇ , and 20.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM lactate is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, or twenty-six XRPD signals selected from those set forth in Table 32,
  • the present disclosure provides solid forms of DOM L-malate Form
  • the DOM L-malate Form 1 e.g., crystalline forms of DOM L-malate Form 1 .
  • the DOM L-malate Form 1 XRPD profile is substantially similar to that shown in FIG. 11.
  • the DOM L-malate Form 1 1 H NMR spectrum is substantially similar to that shown in FIG. 42.
  • the DOM L-malate Form 1 TGA profile is substantially similar to that shown in FIG. 43.
  • the DOM L-malate Form 1 DSC profile is substantially similar to that shown in FIG. 43.
  • the solid form of DOM L-malate Form 1 is crystalline DOM L- malate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.2 °2 ⁇ , 12.6 °2 ⁇ , and 15.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ : Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is crystalline DOM L- malate Form 1 characterized, by XRPD signals at 4.2 °2 ⁇ , 12.6 °2 ⁇ , and. 15.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is crystalline DOM L- malate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 4.2 °2 ⁇ , 12.6 °2 ⁇ , 15.2 °2 ⁇ , 16.6 °2 ⁇ , and 24.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is crystalline DOM L-malate Form 1 characterized by XRPD signals at 4.2 °2 ⁇ , 12,6 °2 ⁇ , 15.2 °2 ⁇ , 16.6 °2 ⁇ , and 24.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is crystalline DOM L- malate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 4.2 °2 ⁇ , and 16.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is crystalline DOM L- malate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 4.2 °2 ⁇ , and 16.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is crystalline DOM L- malate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 4.2 °2 ⁇ , 16.6 °2 ⁇ , 24.7 °2 ⁇ , and 22.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is DOM L-malate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 4.2 °2 ⁇ , 16.6 °2 ⁇ , 24.7 °2 ⁇ , and 22.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is cry stalline DOM L- malate Form I characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 4.2 °2 ⁇ , 16.6 °2 ⁇ , 24.7 °2 ⁇ , 22.8 °2 ⁇ , 21.5 °2 ⁇ , and 23.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L- malate Form 1 is DOM L-malate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 4.2 °2 ⁇ , 16.6 °2 ⁇ , 24.7 °2 ⁇ , 22.8 °2 ⁇ , 21.5 °2 ⁇ , and 23.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ : or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is crystalline DOM L- malate Form 1 characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.6 °2 ⁇ , 4.2 °2 ⁇ , 16.6 °2 ⁇ , 24.7 °2 ⁇ , 22.8 °2 ⁇ , 21.5 °2 ⁇ , 23.8 °2 ⁇ , 15.2 °2 ⁇ , 25.9 °2 ⁇ , and 25.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ . ⁇ 0.1 °2 ⁇ : or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 1 is DOM L-malate Form 1 characterized by XRPD signals at 12.6 °2 ⁇ , 4.2 °2 ⁇ , 16.6 °2 ⁇ , 24.7 °2 ⁇ , 22.8 °2 ⁇ , 21.5 °2 ⁇ , 23.8 °2 ⁇ , 15.2 °2 ⁇ , 25.9 °2 ⁇ , and 25.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM L-malate Form 1 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, or thirty XRPD signals selected from those set forth in Table 33.
  • the present disclosure provides solid, forms of DOM L-malate Forms 1 and 2, e.g., crystalline forms of DOM L-malate Forms 1 and 2.
  • the XRPD profile of a mixture of DOM L-malate Forms 1 and 2 is substantially similar to that shown in FIG. 77.
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and. 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.4 °2 ⁇ , 14.9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by XRPD signals at 14.4 °2 ⁇ , 14.9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 13.2 °2 ⁇ , 14.4 °2 ⁇ , 14,9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by XRPD signals at 3.9 °2 ⁇ , 13.2 °2 ⁇ , 14.4 °2 ⁇ , 14.9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , and 24.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu Kai radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , and 24.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 16.6 °2 ⁇ , and 21.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 20. 16.6 °2 ⁇ , and 21.4 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized, by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 16.6 °2 ⁇ , 21.4 °2 ⁇ , 22.8 °2 ⁇ , and. 4.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 16.6 °2 ⁇ , 21.4 °2 ⁇ , 22.8 °2 ⁇ , and 4.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 16,6 °2 ⁇ , 21 .4 °2 ⁇ , 22.8 °2 ⁇ , 4. 1 °2 ⁇ , 25.8 °2 ⁇ , 25.0 °2 ⁇ , and 26.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate is a mixture of crystalline DOM L-malate Forms 1 and 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 16.6 °2 ⁇ , 21.4 °2 ⁇ , 22.8 °2 ⁇ , 4.1 °2 ⁇ , 25.8 °2 ⁇ , 25.0 °2 ⁇ , and 26.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ , Cu K ⁇ 1 radiation).
  • the mixture of crystalline DOM L-malate Forms 1 and 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty- three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty- one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, forty-eight, forty-nine, or fifty XRPD signals selected from those set forth in Table 34. Table 34. XRPD Signals for a mixture of DOM L-malate Forms 1 and 2
  • the solid form of DOM L-malate Form 2 is crystalline DOM L- malate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.4 °2 ⁇ , 14.9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ . ⁇ 0.1 °2 ⁇ . or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L-malate Form 2 characterized by XRPD signals at 14.4 °2 ⁇ , 14.9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ , ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L- malate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 13.2 °2 ⁇ , 14.4 °2 ⁇ , 14.9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L-malate Form 2 characterized by XRPD signals at 3.9 °2 ⁇ , 13.2 °2 ⁇ , 14.4 °2 ⁇ , 14.9 °2 ⁇ , and 15.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L- malate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , and 24.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ . or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L-malate Form 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , and 24.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L- malate Form 2 characterized, by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 25.0 °2 ⁇ , and 26.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0,0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L-malate Form 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 25.0 °2 ⁇ , and 26.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L- malate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 25.0 °2 ⁇ , 26.1 °2 ⁇ , 14.9 °2 ⁇ , and 23.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L- malate Form 2 is crystalline DOM L-malate Form 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 25.0 °2 ⁇ , 26.1 °2 ⁇ , 14.9 °2 ⁇ , and 23.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L- maiate Form 2 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 25.0 °2 ⁇ , 26.1 °2 ⁇ , 14.9 °2 ⁇ , 23.3 °2 ⁇ , 20.6 °2 ⁇ , 15.4 °2 ⁇ , and 2O.1°2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 2 is crystalline DOM L-malate Form 2 characterized by XRPD signals at 3.9 °2 ⁇ , 15.9 °2 ⁇ , 24.5 °2 ⁇ , 25.0 °2 ⁇ , 26.1 °2 ⁇ , 14.9 °2 ⁇ , 23.3 °2 ⁇ , 20.6 °2 ⁇ , 15.4 °2 ⁇ , and 20.1°2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM L-malate Form 2 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one XRPD signals selected from those set forth in Table 34A.
  • the present disclosure provides solid forms of DOM L-malate Form 3, e.g., crystalline forms of DOM L-malate Form 3.
  • the DOM L-malate Form 3 XRPD profile is substantially similar to that shown in FIG. 78.
  • the solid form of DOM L-malate Form 3 is crystalline DOM L- malate Form 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5,9 °2 ⁇ , 1 1.8 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is crystalline DOM L- malate Form 3 characterized by XRPD signals at 5.9 °2 ⁇ , 1 1.8 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is crystalline DOM L- malate Form 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 3.9 °2 ⁇ , 4.3 °2 ⁇ , 5.9 °2 ⁇ , 11.8 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is crystalline DOM L-malate Form 3 characterized by XRPD signals at 3.9 °2 ⁇ , 4.3 °2 ⁇ , 5.9 °2 ⁇ , 11.8 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is cry stalline DOM L- malate Form 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °2 ⁇ , 23.7 °2 ⁇ , and 11.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ . or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is crystalline DOM L- malate Form 3 characterized by XRPD signals at 5.9 °2 ⁇ , 23.7 °2 ⁇ , and 11.8 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is crystalline DOM L- malate Form 3 characterized, by two or more, or three or more XR PD signals selected from the group consisting of 5.9 °2 ⁇ , 23.7 °2 ⁇ , 11.8 °2 ⁇ , 13.8 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is DOM L-malate Form 3 characterized by XRPD signals at 5.9 °2 ⁇ , 23.7 °2 ⁇ , 11.8 °2 ⁇ , 13.8 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is crystalline DOM L- malate Form 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °2 ⁇ , 23.7 °2 ⁇ , 11.8 °2 ⁇ , 13.8 °2 ⁇ , 16.7 °2 ⁇ , 24.6 °2 ⁇ , and 13.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L- malate Form 3 is DOM L-malate Form 3 characterized by XRPD signals at 5.9 °2 ⁇ , 23.7 °2 ⁇ , 11.8 °2 ⁇ , 13.8 °2 ⁇ , 16.7 °2 ⁇ , 24.6 °2 ⁇ , and 13.6 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L-malate Form 3 is crystalline DOM L- malate Form 3 characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °2 ⁇ , 23.7 °2 ⁇ , 11.8 °2 ⁇ , 13.8 °2 ⁇ , 16.7 °2 ⁇ , 24.6 °2 ⁇ , 13.6 °2 ⁇ , 4.3 °2 ⁇ , 14.2 °2 ⁇ , and 3.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM L, -malate Form 3 is DOM L, -malate Form 3 characterized by XRPD signals at 5.9 °2 ⁇ , 23.7 °2 ⁇ , 11.8 °2 ⁇ , 13.8 °2 ⁇ , 16.7 °2 ⁇ , 24.6 °2 ⁇ , 13.6 °2 ⁇ , 4.3 °2 ⁇ , 14.2 °2 ⁇ , and 3.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM L, -malate Form 3 is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty- five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty- three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, or forty-five XRPD signals selected from those set forth in Table 35.
  • the present disclosure provides solid forms of DOM Form A, e.g., crystalline forms of DOM Form A.
  • the DOM Form A XRPD profile is substantially similar to that shown in FIG. 72.
  • the DOM Form A 1 H NMR spectrum is substantially similar to that shown in FIG. 74.
  • the DOM Form .A TGA profile is substantially similar to that shown in FIG. 75.
  • the DOM Form A DSC profile is substantially similar to that shown in FIG. 75.
  • the DOM Form A FT-IR spectrum is substantially similar to that shown in FIG. 76.
  • the solid form of DOM Form .A is crystalline DOM Form A characterized by two or more, or three or more XRPD signals selected from the group consisting of 12.0 °2 ⁇ , 12.5 °2 ⁇ , and 17.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 20; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is crystalline DOM Form A characterized by XRPD signals at 12.0 °2 ⁇ , 12.5 °2 ⁇ , and 17.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is crystalline DOM Form A characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.8 °2 ⁇ , 11.5 °2 ⁇ , 12.0 °2 ⁇ , 12.5 °2 ⁇ , and 17.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 20; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is crystalline DOM Form A.
  • the solid form of DOM Form A is crystalline DOM Form A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.5 °2 ⁇ , 12.0 °2 ⁇ , and 17.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0. 1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is crystalline DOM Form A characterized by XRPD signals at 11.5 °2 ⁇ , 12.0 °2 ⁇ , and 17.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is crystalline DOM Form A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.5 °2 ⁇ , 12.0 °2 ⁇ , 17.2 °2 ⁇ , 17.4 °2 ⁇ , and 24.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is DOM Form A characterized by XRPD signals at 11.5 °2 ⁇ , 12.0 °2 ⁇ , 17.2 °2 ⁇ , 17.4 °2 ⁇ , and 24.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is crystalline DOM Form A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.5 °2 ⁇ , 12.0 °2 ⁇ , 17.2 °2 ⁇ , 17.4 °2 ⁇ , 24.9 °2 ⁇ , 20.1 °2 ⁇ . and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is DOM Form A characterized by XRPD signals at 11.5 °2 ⁇ , 12.0 °2 ⁇ , 17.2 °2 ⁇ , 17.4 °2 ⁇ , 24.9 °2 ⁇ , 20.1 °2 ⁇ , and 21.1 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form .A is crystalline DOM Form A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.5 °2 ⁇ , 12.0 °2 ⁇ , 17.2 °2 ⁇ , 17.4 °2 ⁇ , 24.9 °2 ⁇ , 20.1 °2 ⁇ , 21.1 °2 ⁇ , 12.5 °2 ⁇ , 24.2 °2 ⁇ , and 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOM Form A is DOM Form A characterized by XRPD signals at 11.5 °2 ⁇ , 12.0 °2 ⁇ , 17.2 °2 ⁇ , 17.4 °2 ⁇ , 24.9 °2 ⁇ , 20.1 °2 ⁇ , 21.1 °2 ⁇ , 12.5 °2 ⁇ , 24.2 °2 ⁇ , and 23.9 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOM Form A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, or thirty XRPD signals selected from those set forth in Table 36.
  • the present disclosure provides solid forms of DOI HCI, e.g., crystalline forms of DOI HCI.
  • the DOI HCI XRPD profile is substantially similar to that, shown in FIG. 79.
  • the solid form of DOI HCI is crystalline DOI HCI characterized by two or more, or three or more XRPD signals selected from the group consisting of 7.8 °2 ⁇ , 8.2 °2 ⁇ , and 10.2 °2 ⁇ (. ⁇ 0.2 °2 ⁇ ; . ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is crystalline DOI HCI characterized by XRPD signals at 7.8 °2 ⁇ , 8.2 °2 ⁇ , and 10.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is cry stalline DOI HCI characterized by two or more, or three or more XRPD signals selected from the group consisting of 7.8 °2 ⁇ , 8.2 °2 ⁇ , 10.2 °2 ⁇ , 19.4 °2 ⁇ , and. 23.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is crystalline DOI HCI characterized by XRPD signals at 7.8 °2 ⁇ , 8.2 29. 10.2 °2 ⁇ , 19.4 20, and 23.5 29 ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is crystalline DOI HCI characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.5 °2 ⁇ , 7.8 °2 ⁇ , and 16.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is crystalline DOI HCI characterized by XRPD signals at 23.5 °2 ⁇ , 7.8 °2 ⁇ , and 16.5 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is cry stalline DOI HCI characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.5 °2 ⁇ , 7.8 °2 ⁇ , 16.5 °2 ⁇ , 22.7 °2 ⁇ , and 16.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is DOI HCI characterized by XRPD signals at of 23.5 °2 ⁇ , 7.8 °2 ⁇ . 16.5 °2 ⁇ , 22.7 °2 ⁇ . and 16.3 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is crystalline DOI HCI characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.5 °2 ⁇ , 7.8 °2 ⁇ , 16.5 °2 ⁇ , 22.7 °2 ⁇ , 16.3 °2 ⁇ , 26.8 °2 ⁇ , and 24.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is DOI HCI characterized by XRPD signals at 23.5 °2 ⁇ , 7.8 °2 ⁇ , 16.5 °2 ⁇ , 22.7 °2 ⁇ , 16.3 °2 ⁇ , 26.8 °2 ⁇ , and 24.2 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is crystalline DOI HCI characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.5 °2 ⁇ , 7.8 °2 ⁇ , 16.5 °2 ⁇ , 22.7 °2 ⁇ , 16.3 °2 ⁇ , 26.8 °2 ⁇ , 24.2 °2 ⁇ , 19.4 °2 ⁇ , 16.1 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0,1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the solid form of DOI HCI is DOI HCI characterized by XRPD signals at 23.5 °2 ⁇ , 7.8 °2 ⁇ , 16.5 °2 ⁇ , 22.7 °2 ⁇ , 16.3 °2 ⁇ , 26.8 °2 ⁇ , 24.2 °2 ⁇ , 19.4 °2 ⁇ , 16.1 °2 ⁇ , and 16.7 °2 ⁇ ( ⁇ 0.2 °2 ⁇ ; ⁇ 0.1 °2 ⁇ ; or ⁇ 0.0 °2 ⁇ ; Cu K ⁇ 1 radiation).
  • the crystalline DOI HCI is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty-two, thirty-three, thirty-four, thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, forty-eight, forty-nine, fifty, fifty-one, fifty-two, fifty-three, fifty-four, or fifty-five XRPD signals selected from those set forth in Table 37.
  • compositions and Formulations in some embodiments, provides a pharmaceutical composition comprising one or more of the solid forms of DOM, DOI, DOB, or DOC, illustrated above, and a pharmaceutically acceptable excipient.
  • Such compositions are suitable for administration to a subject, such as a human subject.
  • the presently disclosed pharmaceutical compositions can be prepared in a wide variety of oral, parenteral and topical dosage forms. Oral preparations include tablets, pills, powder, capsules, lozenges, cachets, slurries, suspensions, etc., suitable for ingestion by the patient.
  • the compositions of the present disclosure can also be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
  • compositions described herein can be administered by inhalation, for example, intranasally. Additionally, the compositions of the present disclosure can be administered transdermally.
  • the compositions of this disclosure can also be administered by intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations (for examples of steroid inhalants, see Rohatagi, J. Clin. Pharmacol. 35:1187-1193, 1995; Tjwa, Ann. Allergy Asthma Immunol. 75:107-111, 1995).
  • the present disclosure also provides pharmaceutical compositions including a pharmaceutically acceptable carrier or excipient and the solid form of DOM, DOI, DOB, or DOC of the present disclosure.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e.g., the latest edition of Remington's Pharmaceutical Sciences, Mack Publishing Co, Easton PA ("Remington's").
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from 5% to 70% or 10% to 70% of the compounds of the present disclosure.
  • suitable solid excipients include, but are not limited to, magnesium carbonate; magnesium stearate; talc; pectin; dextrin; starch; tragacanth; a low melting wax; cocoa butter; carbohydrates; sugars including, but not limited to, lactose, sucrose, mannitol, or sorbitol, starch from com, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins including, but not limited to, gelatin and collagen.
  • disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include suspensions, for example, water or water/propylene glycol suspensions.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty
  • the aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin.
  • preservatives such as ethyl or n-propyl p-hydroxybenzoate
  • coloring agents such as ethyl or n-propyl p-hydroxybenzoate
  • flavoring agents such as sucrose, aspartame or saccharin.
  • sweetening agents such as sucrose, aspartame or saccharin.
  • Formulations can be adjusted for osmolarity.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • Such liquid forms include suspensions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thicken
  • Oil suspensions can be formulated by suspending the compound of the present disclosure in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these.
  • the oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose.
  • These formulations can be preserved by the addition of an antioxidant such as ascorbic acid.
  • an injectable oil vehicle see Minto, J. Pharmacol. Exp. Ther.281:93-102, 1997.
  • the pharmaceutical formulations of the disclosure can also be in the form of oil-in-water emulsions.
  • the oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate.
  • the emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs.
  • compositions of the present disclosure can also be delivered as microspheres for slow release in the body.
  • microspheres can be formulated for administration via intradermal injection of drug- containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed.7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res.12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol.49:669-674, 1997).
  • the pharmaceutical compositions of the present disclosure can be formulated for parenteral administration, such as intravenous (IV) administration or administration into a body cavity or lumen of an organ.
  • parenteral administration such as intravenous (IV) administration or administration into a body cavity or lumen of an organ.
  • the formulations for administration will commonly comprise a solution or suspension of the compositions of the present disclosure dissolved or suspended in a pharmaceutically acceptable carrier.
  • acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride.
  • sterile fixed oils can conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions or suspensions are sterile and generally free of undesirable matter.
  • These formulations may be sterilized by conventional, well known sterilization techniques.
  • the formulations may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of the compositions of the present disclosure in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs.
  • the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, such as a solution of 1,3- butanediol.
  • the formulations of the compositions of the present disclosure can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, for example, by employing ligands attached to the liposome, or attached directly to the oligonucleotide, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
  • liposomes particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present disclosure into the target cells in vivo. (See, e.g., Al-Muhammed, J. Microencapsul.13:293-306, 1996; Chonn, Curr.
  • compositions of the present disclosure can be administered by any suitable means, including oral, parenteral and topical methods.
  • Transdermal administration methods by a topical route, can be formulated as applicator sticks, suspensions, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • the pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the compounds of the present disclosure.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the compound of the present disclosure can be present in any suitable amount, and can depend on various factors including, but not limited to, weight and age of the subject, state of the disease, and the like as is known to those of ordinary skill in the art.
  • the DOM, DOI, DOB, or DOC forms administered herein typically are administered to provide from between about 0.5 mg and about 35 mg, or about 1mg, or about 2mg, or about 3mg, or about 4mg, or about 5 mg, or about 6mg, or about 7mg, or about 8mg, or about 9mg, or about 10mg, or about 11mg, or about 12mg, or about 13mg, or about 14mg, or about 15mg 20mg, or about 25mg, or about 30mg, or about 35 mg.
  • Suitable dosage ranges for the compounds disclosed herein include from about 0.1 mg to about 10,000 mg, or about 1 mg to about 1000 mg, or about 10 mg to about 750 mg, or about 25 mg to about 500 mg, or about 50 mg to about 250 mg.
  • Suitable dosages for the compound of the present invention include about 1 mg, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 mg.
  • the compounds disclosed herein can be administered at any suitable frequency, interval and duration. For example, the compounds can be administered once an hour, or two, three or more times an hour, once a day, or two, three, or more times per day, or once every 2, 3, 4, 5, 6, or 7 days, so as to provide the preferred dosage level.
  • representative intervals include 5, 10, 15, 20, 30, 45 and 60 minutes, as well as 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24 hours.
  • the compound of the present invention can be administered once, twice, or three or more times, for an hour, for 1 to 6 hours, for 1 to 12 hours, for 1 to 24 hours, for 6 to 12 hours, for 12 to 24 hours, for a single day, for 1 to 7 days, for a single week, for 1 to 4 weeks, for a month, for 1 to 12 months, for a year or more, or even indefinitely.
  • the composition can also contain other compatible therapeutic agents.
  • the compounds described herein can be used in combination with one another, with other active agents known to be useful in modulating a glucocorticoid receptor, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
  • the compounds of the present disclosure can be co-administered with a second active agent.
  • Co-administration includes administering the compound of the present disclosure and active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of each other.
  • Co-administration also includes administering the compound of the present disclosure and active agent simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order.
  • the compound of the present disclosure and the active agent can each be administered once a day, or two, three, or more times per day so as to provide the preferred dosage level per day.
  • co-administration can be accomplished by co-formulation, such as by preparing a single pharmaceutical composition including both the compound of the present disclosure and a second active agent.
  • the compound of the present disclosure and the second active agent can be formulated separately.
  • the disclosed compounds and the second active agent can be present in the compositions of the present disclosure in any suitable weight ratio, such as from about 1:100 to about 100: 1 (w/w), or about 1 :50 to about 50: 1, or about 1 :25 to about 25: 1, or about 1:10 to about 10:1, or about 1:5 to about 5:1 (w/w).
  • the compound of the present disclosure and the second active agent can be present in any suitable weight ratio, such as about 1: 100 (w/w), 1:50, 1:25, 1:10, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 25:1, 50:1 or 100:1 (w/w).
  • compositions and methods disclosed herein are suitable in the compositions and methods disclosed herein.
  • V. Methods of Treatment The solid forms of DOM, DOI, DOB, or DOC of the present disclosure can be used for increasing neuronal plasticity.
  • the compounds of the present disclosure can also be used to treat any brain disease.
  • the compounds of the present disclosure can also be used for increasing at least one of translation, transcription or secretion of neurotrophic factors.
  • the methods described herein are for treating a disease or disorder that is a brain disease or disorder.
  • the methods described herein are for increasing at least one of translation, transcription or secretion of neurotrophic factors.
  • the compositions provided herein have, for example, anti- addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof.
  • the brain disorder is a neuropsychiatric disease.
  • the methods described herein are for treating a disease or disorder that is a neuropsychiatric disease.
  • the neuropsychiatric disease is a mood or anxiety disorder.
  • brain disorders include, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), anxiety, depression, panic disorder, suicidality, schizophrenia, and addiction (e.g., substance abuse disorder).
  • brain disorders include, for example, migraines, addiction (e.g., substance use disorder for example alcohol abuse, opiate addition, or abuse), depression, and anxiety.
  • the brain disease or disorder is a neurodegenerative disorder, Alzheimer’s disease or Parkinson’s disease.
  • the brain disease or disorder is psychological disorder, depression, addiction, anxiety, or a post-traumatic stress disorder.
  • the brain disorder is depression.
  • the brain disorder is addiction.
  • the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury or substance use disorder.
  • the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder.
  • the brain disorder is stroke or traumatic brain injury.
  • the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, or substance use disorder.
  • the brain disorder is schizophrenia.
  • the brain disorder is alcohol use disorder.
  • a compound of the present disclosure is used to treat neurological diseases.
  • the methods described herein are for treating a disease or disorder that is a neurological disease.
  • a compound provided herein can exhibit, anti-addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof.
  • the neurological disease is a neuropsychiatric disease.
  • the neuropsychiatric disease is a mood or anxiety disorder.
  • the neurological disease is a migraine, headaches (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disorder, Alzheimer’s disease, Parkinson’s disease, psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, hypoxic brain injury, Chronic traumatic encephalopathy (CTE), traumatic brain injury, dementia, and addiction (e.g., substance use disorder).
  • the neurological disease is a migraine or cluster headache.
  • the neurological disease is a neurodegenerative disorder, dementia, Alzheimer’s disease, or Parkinson’s disease.
  • the neurological disease is dementia.
  • the neurological disease is a psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety.
  • the neuropsychiatric disease is a psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety.
  • the neuropsychiatric disease or neurological disease is post- traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), schizophrenia, depression, or anxiety.
  • the neuropsychiatric disease or neurological disease is addiction (e.g., substance use disorder).
  • the neuropsychiatric disease or neurological disease is depression.
  • the neuropsychiatric disease or neurological disease is anxiety.
  • the neuropsychiatric disease or neurological disease is post-traumatic stress disorder (PTSD).
  • the neurological disease is stroke or traumatic brain injury.
  • the neuropsychiatric disease or neurological disease is schizophrenia.
  • the methods described herein are for increasing neuronal plasticity and has, for example, anti-addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof. In some embodiments, decreased neuronal plasticity is associated with a neuropsychiatric disease. In some embodiments, a compound of the present disclosure is used for increasing neuronal plasticity. In some embodiments, the compounds described herein are used for treating a brain disorder. In some embodiments, the compounds described herein are used for increasing at least one of translation, transcription, or secretion of neurotrophic factors. In some embodiments, the present disclosure provides a method of treating a disease, including administering to a subject in need thereof, a therapeutically effective amount of a compound of the present disclosure.
  • the disease is a musculoskeletal pain disorder including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, and muscle cramps.
  • the present disclosure provides a method of treating a disease of women’s reproductive health including premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), post-partum depression, and menopause.
  • PMDD premenstrual dysphoric disorder
  • PMS premenstrual syndrome
  • post-partum depression post-partum depression
  • menopause menopause.
  • Diseases of particular interest include depression and related conditions.
  • the disease or disorder treated herein is depression or a disease or disorder related to depression.
  • the depression is major depressive disorder, persistent depressive disorder, bipolar disorder, treatment resistant depression (TRD), postpartum depression, premenstrual dysphoric disorder, or seasonal affective disorder.
  • the disease or disorder related to depression is anxiety.
  • methods of treating depression or a disease or disorder related to depression comprise treating the symptoms associated with the depression or the disease or disorder related to depression. Described herein are methods of treating depression or a disease or disorder related to depression in a subject in need thereof, the method comprising administering to the subject a psychedelic and a serotonin receptor modulator, wherein the serotonin receptor modulator is administered at most about 3 hours prior to the release of the psychedelic.
  • the depression is major depressive disorder, persistent depressive disorder, bipolar disorder, treatment resistant depression (TRD), postpartum depression, premenstrual dysphoric disorder, or seasonal affective disorder.
  • the disease or disorder related to depression is anxiety.
  • methods of treating depression or a disease or disorder related to depression comprise treating the symptoms associated with the depression or the disease or disorder related to depression.
  • the DOM, DOI, DOB, or DOC solid forms of the present disclosure have activity as 5-HT 2A modulators.
  • the compounds of the present disclosure elicit a biological response by activating the 5-HT 2A receptor (e.g., allosteric modulation or modulation of a biological target that activates the 5-HT 2A receptor).
  • 5-HT 2A agonism has been correlated with the promotion of neural plasticity (Ly et al., 2018).
  • 5-HT 2A antagonists abrogate the neuritogenesis and spinogenesis effects of hallucinogenic compounds with 5-HT 2A agonist activity, for example., DMT or LSD.
  • the compounds of the present disclosure are 5-HT 2A modulators and promote neural plasticity (e.g., cortical structural plasticity).
  • the compounds of the present disclosure are selective 5-HT 2A modulators and promote neural plasticity (e.g., cortical structural plasticity).
  • promotion of neural plasticity includes, for example, increased dendritic spine growth, increased synthesis of synaptic proteins, strengthened synaptic responses, increased dendritic arbor complexity, increased dendritic branch content, increased spinogenesis, increased neuritogenesis, or any combination thereof.
  • increased neural plasticity includes, for example, increased cortical structural plasticity in the anterior parts of the brain.
  • the 5-HT 2A modulators e.g., 5-HT 2A agonists
  • non-hallucinogenic 5-HT 2A modulators are used to treat neurological diseases, which modulators do not elicit dissociative side- effects.
  • the hallucinogenic potential of the compounds described herein is assessed in vitro. In some embodiments, the hallucinogenic potential assessed in vitro of the compounds described herein is compared to the hallucinogenic potential assessed in vitro of hallucinogenic homologs. In some embodiments, the compounds described herein elicit less hallucinogenic potential in vitro than the hallucinogenic homologs.
  • serotonin receptor modulators such as modulators of serotonin receptor 2A (5-HT 2A modulators, e.g., 5-HT 2A agonists), are used to treat a brain disorder.
  • the presently disclosed compounds can function as 5-HT 2A agonists alone, or in combination with a second therapeutic agent that also is a 5-HT 2A modulator.
  • the second therapeutic agent can be an agonist or an antagonist.
  • Serotonin receptor modulators useful as second therapeutic agents for combination therapy as described herein are known to those of skill in the art and include, without limitation, ketanserin, volinanserin (MDL-100907), eplivanserin (SR-46349), pimavanserin (ACP-103), glemanserin (MDL-11939), ritanserin, flibanserin, nelotanserin, blonanserin, mianserin, mirtazapine, roluperiodone (CYR-101, MIN-101), quetiapine, olanzapine, altansenn, acepromazine, nefazodone, risperidone, pruvansenn, AC-90179, AC-279, adatansenn, fananserin, HY10275, benanserin, butanserin, manserin, iferanserin, lidanserin, pelanserin, segansenn, tropanserin, lor
  • the serotonin receptor modulator is ketanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.
  • the serotonin receptor modulator is pimavanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.
  • the serotonin receptor modulator is eplivanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof.
  • the serotonin receptor modulator is flibanserin or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof. In some embodiments, the serotonin receptor modulator is roluperiodone or a. pharmaceutically acceptable salt, solvate, metabolite, deuterated analogue, derivative, or prodrug thereof. In some embodiments, the serotonin receptor modulator is administered prior to a compound disclosed herein, such as about one or about three hours prior to administration of a compound disclosed herein. In some embodiments, the serotonin receptor modulator is administered at most about one hour prior to the presently disclosed compound. Thus, in some embodiments of combination therapy with the presently disclosed compounds, the second therapeutic agent is a serotonin receptor modulator.
  • the second therapeutic agent serotonin receptor modulator is provided at a. dose of from about 10 mg to about 350 mg. In some embodiments, the serotonin receptor modulator is provided at a. dose of from about 20 mg to about 200 mg. In some embodiments, the serotonin receptor modulator is provided at a dose of from about 10 mg to about 100 mg. In certain such embodiments, the compound of the present disclosure is provided at a dose of from about 10 mg to about 100 mg, or from about 20 to about 200 mg, or from about 15 to about 300 mg, and the serotonin receptor modulator is provided at a dose of about 10 mg to about 100 mg.
  • non-hallucinogenic 5-HT2 A modulators are used to treat neurological diseases.
  • the neurological diseases comprise decreased neural plasticity, decreased cortical structural plasticity, decreased 5-HT 2A receptor content, decreased dendritic arbor complexity, loss of dendritic spines, decreased dendritic branch content, decreased spinogenesis, decreased neuritogenesis, retraction of neurites, or any combination thereof.
  • non-hallucinogenic 5-HT 2A modulators e.g., 5-HT 2A agonists
  • non-hallucinogenic 5-HT 2A modulators are used for treating a brain disorder.
  • non-hallucinogenic 5-HT 2A modulators e.g., 5-HT 2A agonists
  • the presently disclosed compounds are given to patients in a low dose that is lower than would produce noticeable psychedelic effects but high enough to provide a therapeutic benefit. This dose range is predicted to be between 200ug (micrograms) and 2mg.
  • Neuronal plasticity refers to the ability of the brain to change structure and/or function throughout a subject’s life. New neurons can be produced and integrated into the central nervous system throughout the subject’s life. Increasing neuronal plasticity includes, but is not limited to, promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendritogenesis, increasing dendritic arbor complexity, increasing dendritic spine density, and increasing excitatory synapsis in the brain.
  • increasing neuronal plasticity comprises promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendritogenesis, increasing dendritic arbor complexity, and increasing dendritic spine density.
  • increasing neuronal plasticity by treating a subject with one or more of the disclosed compound can treat neurodegenerative disorder, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, addiction, anxiety, post-traumatic stress disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder.
  • the present disclosure provides methods for increasing neuronal plasticity, comprising contacting a neuronal cell with a compound of the present disclosure.
  • increasing neuronal plasticity improves a brain disorder described herein.
  • a compound of the present disclosure is used to increase neuronal plasticity.
  • the compounds used to increase neuronal plasticity have, for example, anti- addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof.
  • decreased neuronal plasticity is associated with a neuropsychiatric disease.
  • the neuropsychiatric disease is a mood or anxiety disorder.
  • the neuropsychiatric disease includes, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), schizophrenia, anxiety, depression, and addiction (e.g., substance abuse disorder).
  • brain disorders include, for example, migraines, addiction (e.g., substance use disorder), depression, and anxiety.
  • the experiment or assay to determine increased neuronal plasticity of any compound of the present disclosure is a phenotypic assay, a dendritogenesis assay, a spinogenesis assay, a synaptogenesis assay, a Sholl analysis, a concentration-response experiment, a 5-HT 2A agonist assay, a 5-HT 2A antagonist assay, a 5-HT 2A binding assay, or a 5- HT 2A blocking experiment (e.g., ketanserin blocking experiments).
  • the experiment or assay to determine the hallucinogenic potential of any compound of the present disclosure is a mouse head-twitch response (HTR) assay.
  • the present disclosure provides a method for increasing neuronal plasticity, comprising contacting a neuronal cell with a compound disclosed herein.
  • B) Methods of Treating a Brain Disorder In some embodiments, the present disclosure provides a method of treating a disease, including administering to a subject in need thereof, a therapeutically effective amount of DOM, DOI, DOB, or DOC of the present disclosure.
  • the disease is a musculoskeletal pain disorder including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, and muscle cramps.
  • the present disclosure provides a method of treating a disease of women’s reproductive health including premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), post-partum depression, and menopause.
  • the present disclosure provides a method of treating a brain disorder, including administering to a subject in need thereof, a therapeutically effective amount of a compound of the present disclosure.
  • the present disclosure provides a method of treating a brain disorder with combination therapy, including administering to a subject in need thereof, a therapeutically effective amount of a compound of the present disclosure and at least one additional therapeutic agent.
  • 5-HT 2A modulators e.g., 5-HT 2A agonists
  • the brain disorders comprise decreased neural plasticity, decreased cortical structural plasticity, decreased 5-HT 2A receptor content, decreased dendritic arbor complexity, loss of dendritic spines, decreased dendritic branch content, decreased spinogenesis, decreased neuritogenesis, retraction of neurites, or any combination thereof.
  • a compound of the present disclosure is used to treat brain disorders.
  • the compounds have, for example, anti- addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof.
  • the brain disorder is a neuropsychiatric disease.
  • the neuropsychiatric disease is a mood or anxiety disorder.
  • brain disorders include, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), anxiety, depression, panic disorder, suicidality, schizophrenia, and addiction (e.g., substance abuse disorder).
  • brain disorders include, for example, migraines, addiction (e.g., substance use disorder), depression, and anxiety.
  • the present disclosure provides a method of treating a brain disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein.
  • the brain disorder is a neurodegenerative disorder, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, addiction, anxiety, post-traumatic stress disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder.
  • the brain disorder is a neurodegenerative disorder, Alzheimer’s, or Parkinson’s disease.
  • the brain disorder is a psychological disorder, depression, addiction, anxiety, or a post-traumatic stress disorder.
  • the brain disorder is depression.
  • the brain disorder is addiction. In some embodiments, the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury or substance use disorder. In some embodiments, the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder. In some embodiments, the brain disorder is stroke or traumatic brain injury. In some embodiments, the brain disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, or substance use disorder. In some embodiments, the brain disorder is schizophrenia. In some embodiments, the brain disorder is alcohol use disorder.
  • the method further comprises administering one or more additional therapeutic agent that is lithium, olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), ariprazole (Abilify), ziprasidone (Geodon), clozapine (Clozaril), divalproex sodium (Depakote), lamotrigine (Lamictal), valproic acid (Depakene), carbamazepine (Equetro), topiramate (Topamax), levomilnacipran (Fetzima), duloxetine (Cymbalta, Yentreve), venlafaxine (Effexor), citalopram (Celexa), fluvoxamine (Luvox), escitalopram (Lexapro), fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), clomipramine (Anafranil),
  • suitable empathogenic agents for use in combination with the present solid forms include phenethylamines, such as 3,4-methylene- dioxymethamphetamine (MDMA), and analogs thereof.
  • suitable empathogenic agents for use in combination with the presently disclosed compounds include, without limitation, N-Allyl-3,4-methylenedioxy-amphetamine (MDAL) N-Butyl-3,4-methylenedioxyamphetamine (MDBU) N-Benzyl-3,4-methylenedioxyamphetamine (MDBZ) N-Cyclopropylmethyl-3,4-methylenedioxyamphetamine (MDCPM) N,N-Dimethyl-3,4-methylenedioxyamphetamine (MDDM) N-Ethyl-3,4-methylenedioxyamphetamine (MDE; MDEA) N-(2-Hydroxyethyl)-3,4-methylenedioxy amphetamine (MDHOET) N-Isopropyl-3,4
  • the compounds of the present disclosure are used in combination with the standard of care therapy for a neurological disease described herein.
  • the standard of care therapies may include, for example, lithium, olanzapine, quetiapine, risperidone, ariprazole, ziprasidone, clozapine, divalproex sodium, lamotrigine, valproic acid, carbamazepine, topiramate, levomilnacipran, duloxetine, venlafaxine, citalopram, fluvoxamine, escitalopram, fluoxetine, paroxetine, sertraline, clomipramine, amitriptyline, desipramine, imipramine, nortriptyline, phenelzine, tranylcypromine, diazepam, alprazolam, clonazepam, or any combination thereof.
  • Nonlimiting examples of standard of care therapy for depression are sertraline, fluoxetine, escitalopram, venlafaxine, or aripiprazole.
  • Non-limiting examples of standard of care therapy for depression are citralopram, escitalopram, fluoxetine, paroxetine, diazepam, or sertraline. Additional examples of standard of care therapeutics are known to those of ordinary skill in the art.
  • C) Methods of increasing at least one of translation, transcription, or secretion of neurotrophic factors refers to a family of soluble peptides or proteins which support the survival, growth, and differentiation of developing and mature neurons.
  • Increasing at least one of translation, transcription, or secretion of neurotrophic factors can be useful for, but not limited to, increasing neuronal plasticity, promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendritogenesis, increasing dendritic arbor complexity, increasing dendritic spine density, and increasing excitatory synapsis in the brain.
  • increasing at least one of translation, transcription, or secretion of neurotrophic factors can increasing neuronal plasticity.
  • increasing at least one of translation, transcription, or secretion of neurotrophic factors can promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendritogenesis, increasing dendritic arbor complexity, and/or increasing dendritic spine density.
  • 5-HT 2A modulators e.g., 5-HT 2A agonists
  • a compound of the present disclosure is used to increase at least one of translation, transcription, or secretion of neurotrophic factors.
  • increasing at least one of translation, transcription or secretion of neurotrophic factors treats a migraine, headaches (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disorder, Alzheimer’s disease, Parkinson’s disease, psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and addiction (e.g., substance use disorder).
  • the experiment or assay used to determine increase translation of neurotrophic factors includes ELISA, western blot, immunofluorescence assays, proteomic experiments, and mass spectrometry.
  • the experiment or assay used to determine increase transcription of neurotrophic factors includes gene expression assays, PCR, and microarrays. In some embodiments, the experiment or assay used to determine increase secretion of neurotrophic factors includes ELISA, western blot, immunofluorescence assays, proteomic experiments, and mass spectrometry. In some embodiments, the present disclosure provides a method for increasing at least one of translation, transcription or secretion of neurotrophic factors, comprising contacting a neuronal cell with a compound disclosed herein. VI. Combination therapy In particular embodiments of treating the disorders described above, combination therapy is used as described herein.
  • a form of DOM, DOI, DOB, or DOC described herein is administered in combination with a serotonin receptor modulator.
  • the serotonin receptor modulator is selected from the group consisting of altanserin, blonanserin, eplivanserin, glemanserin, volinanserin, ketanserin, ritanserin, pimavanserin, nelotanserin, pruvanserin, and flibanserin.
  • the serotonin receptor modulator is selected from the group consisting of serotonin receptor modulator is selected from the group consisting of eplivanserin, volinanserin, ketanserin, ritanserin, pimavanserin, nelotanserin, pruvanserin, flibanserin, olanzapine, quetiapine, risperidone, and buspirone.
  • the serotonin receptor modulator for use with the psychedelic DOM, DOI, DOB, or DOC is eplivanserin and, wherein the eplivanserin is administered in about 1 mg to about 40 mg, or about 5 mg to about 10 mg, and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered in about 1 mg to about 60 mg, or about 5 mg to about 20 mg, and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM, DOI, DOB, or DOC is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM, DOI, DOB, or DOC is ritanserin, wherein the ritanserin is administered in about 1 mg to about 40 mg, or about 2.5 mg to about 10 mg, and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered in about 1 mg to about 60 mg, or about 17 mg to about 34 mg, and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM, DOI, DOB, or DOC is nelotanserin, wherein the nelotanserin is administered in about 1 mg to about 80 mg, or about 40 mg to about 80 mg, and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM, DOI, DOB, or DOC is pruvanserin, wherein the pruvanserin is administered in about 1 mg to about 40 mg, or about 3 mg to about 10 mg, and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM, DOI, DOB, or DOC is flibanserin, wherein the flibanserin is administered in about 10 mg to about 200 mg, or about 80 mg to about 120 mg, or about 100 mg and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM, DOI, DOB, or DOC is buspirone, wherein the buspirone is present between about 1 mg to about 100 mg, or about 1 mg or about 2 mg, or about 3 mg, or about 4 mg, or about 5 mg, or about 6 mg, or about 7 mg, or about 7.5 mg, or about 10 mg, or about 15 mg, or about 22.5 mg, or about 30 mg, or about 37.5 mg, or about 45 mg, or about 52.5 mg, or about 60 mg, or about 1 mg to about 10 mg, or about 5 mg to about 10 mg, or about 10 mg to about 15 mg, or about 15 mg to about 30 mg, or about 30 mg to about 60 mg, or about 60 mg to about 80 mg, or about 80 mg to about 100 mg, and the DOM, DOI, DOB, or DOC is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • a disclosed DOM, DOI, DOB, or DOC form is co-administered with a serotonin receptor modulator in the same or in separate compositions.
  • the DOM, DOI, DOB, or DOC is administered in a modified release formulation such that the subject is effectively pretreated with serotonin receptor modulator prior to release of an effective amount of the psychedelic.
  • the serotonin receptor modulator is administered or released from a composition provided herein prior to the administration and/or release of the psychedelic. This allows pretreatment to attenuate activation of the serotonin receptor by the psychedelic.
  • the serotonin receptor modulator is administered or released from the composition provided herein to pretreat a subject by at least about at about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.25 hours, 1.5 hours, 2 hours, or 3 hours prior to the release of the psychedelic.
  • the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat at most about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, or more than 9 hours prior to the release of the psychedelic.
  • the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat in a range of about 5 minutes to about 3 hours, about 10 minutes to about 3 hours, about 20 minutes to about 3 hours, about 30 minutes to about 3 hours, about 40 minutes to about 3 hours, about 50 minutes to about 3 hours, about 1 hour to about 3 hours, about 5 minutes to about 2 hours, about 10 minutes to about 2 hours, about 20 minutes to about 2 hours, about 30 minutes to about 2 hours, about 40 minutes to about 2 hours, about 50 minutes to about 2 hours, about 1 hour to about 2 hours, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 40 minutes to about 1 hour, or about 50 minutes to about 1 hour prior to the release of the psychedelic.
  • the serotonin receptor modulator is administered at about 1 hour to about 3 hours prior to the administration of the psychedelic.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 15 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat between at least 30 minutes prior and 360 minutes prior to the release or administration of the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat between at least 60 minutes prior and 360 minutes prior to the release or administration the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat between at least 90 minutes and 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 270 minutes prior to DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the eplivanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein eplivanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat a subject between at least 15 minutes and 360 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat between at least 30 minutes and 360 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 90 minutes prior to DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 270 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the volinanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein volinanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 15 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat between at least 30 minutes and 360 minutes prior to the administration or release DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 90 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 270 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ketanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 15 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 30 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 90 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 270 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the ritanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein ritanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 15 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 30 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 90 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 270 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pimavanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein pimavanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 15 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 30 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 90 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 270 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the nelotanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein nelotanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 15 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 30 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 90 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 270 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the pruvanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein pruvanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 15 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 30 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 90 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 120 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 180 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 210 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 240 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 270 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 300 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 330 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein the flibanserin is administered to pretreat at least 360 minutes prior to the DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM, DOI, DOB, or DOC, wherein flibanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of DOM, DOI, DOB, or DOC.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is eplivanserin and, wherein the eplivanserin is administered in about 1 mg to about 40 mg, or about 5 mg to about 10 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator is volinanserin and the psychedelic DOM salt and solid forms disclosed in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein wherein the volinanserin is administered in about 1 mg to about 60 mg, or about 5 mg to about 20 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is ritanserin, wherein the ritanserin is administered in about 1 mg to about 40 mg, or about 2.5 mg to about 10 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator is pimavanserin and the psychedelic DOM salt and solid forms disclosed in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein wherein the pimavanserin is administered in about 1 mg to about 60 mg, or about 17 mg to about 34 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is nelotanserin, wherein the nelotanserin is administered in about 1 mg to about 80 mg, or about 40 mg to about 80 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is pruvanserin, wherein the pruvanserin is administered in about 1 mg to about 40 mg, or about 3 mg to about 10 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is flibanserin, wherein the flibanserin is administered in about 10 mg to about 200 mg, or about 80 mg to about 120 mg, or about 100 mg and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is olanzapine, wherein the olanzapine is administered in about 2.5 mg to about 30 mg, or about 5mg or about 10 mg, or about 20 mg or about 25mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is an extended-release of olanzapine such as ZYPREXA RELPREVV, wherein the extended release olanzapine is administered in about 50 mg to about 450 mg, or about 150 mg or about 210 mg, or about 300 mg or about 405 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • olanzapine such as ZYPREXA RELPREVV
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is quetiapine, wherein the quetiapine is administered in about 25 mg to about 800 mg, or about 50 mg to about 100 mg, or about 150mg or about 200mg or about 250mg or about 300mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is an extended-release of quetiapine, wherein the extended-release of quetiapine is administered in about 50 mg to about 300 mg, or about 50mg or about 100 mg or about 200 mg, or about 300 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is risperidone, wherein the risperidone is administered in about 0.5mg to about 20mg or about .5mg, or about 1mg, or about 2mg, or about 3mg or about 4mg or about 5mg or about 7.5mg or about 10mg or about 16mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is an extended-release of risperidone including RISPERDAL CONSTA, wherein the extended-release of risperidone is administered in about 12.5 mg, or about 25 mg, or about 37.5 mg, or about 50 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein are administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the psychedelic DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is buspirone, wherein the buspirone is present between about 1 mg to about 100 mg, or about 1 mg or about 2 mg, or about 3 mg, or about 4 mg, or about 5 mg, or about 6 mg, or about 7 mg, or about 7.5 mg, or about 10 mg, or about 15 mg, or about 22.5 mg, or about 30 mg, or about 37.5 mg, or about 45 mg, or about 52.5 mg, or about 60 mg, or about 1 mg to about 10 mg, or about 5 mg to about 10 mg, or about 10 mg to about 15 mg, or about 15 mg to about 30 mg, or about 30 mg to about 60 mg, or about 60 mg to about 80 mg, or about 80 mg to about 100 mg, and the DOM salt and solid forms disclosed herein, including those described in Table Ex3B, Ex5B, or Ex
  • a DOM form disclosed herein including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is co-administered with a serotonin receptor modulator in the same or in separate compositions.
  • the serotonin receptor modulator is administered prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein.
  • the DOM form disclosed herein including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl forms disclosed herein is administered in a modified release formulation such that the subject is effectively pretreated with serotonin receptor modulator prior to release of an effective amount of the DOM or DOI.
  • the serotonin receptor modulator is part of a single fixed dose formulation that releases serotonin receptor modulator first followed by the DOM or DOI on two different release profiles.
  • the serotonin receptor modulator is administered first as a single dosage and after a length of time, the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein is administered as a second dosage separate from the first dosage.
  • the serotonin receptor modulator is administered or released from a composition provided herein prior to the administration and/or release of the psychedelic. This allows pretreatment to attenuate activation of the serotonin receptor by the psychedelic.
  • the serotonin receptor modulator is administered or released from the composition provided herein to pretreat a subject by at least about at about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.25 hours, 1.5 hours, 2 hours, or 3 hours prior to the release of the psychedelic.
  • the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat at most about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, or more than 9 hours prior to the release of the psychedelic.
  • the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to pretreat in a range of about 5 minutes to about 3 hours, about 10 minutes to about 3 hours, about 20 minutes to about 3 hours, about 30 minutes to about 3 hours, about 40 minutes to about 3 hours, about 50 minutes to about 3 hours, about 1 hour to about 3 hours, about 5 minutes to about 2 hours, about 10 minutes to about 2 hours, about 20 minutes to about 2 hours, about 30 minutes to about 2 hours, about 40 minutes to about 2 hours, about 50 minutes to about 2 hours, about 1 hour to about 2 hours, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 40 minutes to about 1 hour, or about 50 minutes to about 1 hour prior to the release of the psychedelic.
  • the serotonin receptor modulator is administered at about 1 hour to about 3 hours prior to the administration of the psychedelic.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat between at least 30 minutes prior and 360 minutes prior to the release or administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat between at least 60 minutes prior and 360 minutes prior to the release or administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat between at least 90 minutes and 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 270 minutes prior to DOM.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein eplivanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat a subject between at least 15 minutes and 360 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat between at least 30 minutes and 360 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein volinanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat between at least 30 minutes and 360 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein ritanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein pimavanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein nelotanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein pruvanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein the flibanserin is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM or DOI, wherein flibanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein the olanzapine is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM or DOI, wherein olanzapine is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein the quetiapine is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine and the psychedelic is DOM or DOI, wherein quetiapine is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein the risperidone is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM or DOI, wherein risperidone is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 15 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 30 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 90 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 120 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 180 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 210 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 240 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 270 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 300 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 330 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein the buspirone is administered to pretreat at least 360 minutes prior to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone and the psychedelic is DOM or DOI, wherein buspirone is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • a DOM form disclosed herein including those described in Table Ex3B, Ex5B, or Ex5D, or a DOI HCl form disclosed herein is co-administered with a serotonin receptor modulator in the same or in separate compositions.
  • the serotonin receptor modulator is administered after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or a DOI HCl form disclosed herein.
  • the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein is administered in a modified release formulation such that the subject is effectively post-treated with serotonin receptor modulator post to release of an effective amount of the DOM or DOI.
  • the serotonin receptor modulator is part of a single fixed dose formulation that releases the DOM or DOI first followed by serotonin receptor modulator on two different release profiles.
  • the DOM form disclosed herein including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein is administered first as a single dosage and, after a length of time, serotonin receptor modulator is administered as a second dosage separate from the first dosage.
  • the serotonin receptor modulator is administered or released from a composition provided herein after the administration and/or release of the psychedelic. This allows post-treatment to attenuate activation of the serotonin receptor by the psychedelic.
  • the serotonin receptor modulator is administered or released from the composition provided herein to post-treat a subject by at least about at about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.25 hours, 1.5 hours, 2 hours, or 3 hours after the release of the psychedelic.
  • the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to post-treat at most about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, or more than 9 hours after the release of the psychedelic.
  • the serotonin receptor modulator attenuates the activation of the serotonin receptor when the serotonin receptor modulator is used to post-treat in a range of about 5 minutes to about 3 hours, about 10 minutes to about 3 hours, about 20 minutes to about 3 hours, about 30 minutes to about 3 hours, about 40 minutes to about 3 hours, about 50 minutes to about 3 hours, about 1 hour to about 3 hours, about 5 minutes to about 2 hours, about 10 minutes to about 2 hours, about 20 minutes to about 2 hours, about 30 minutes to about 2 hours, about 40 minutes to about 2 hours, about 50 minutes to about 2 hours, about 1 hour to about 2 hours, about 5 minutes to about 1 hour, about 10 minutes to about 1 hour, about 20 minutes to about 1 hour, about 30 minutes to about 1 hour, about 40 minutes to about 1 hour, or about 50 minutes to about 1 hour after the release of the psychedelic.
  • the serotonin receptor modulator is administered at about 1 hour to about 3 hours after the administration of the psychedelic.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 15 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat between at least 30 minutes after and 360 minutes after the release or administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat between at least 60 minutes after and 360 minutes after the release or administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat between at least 90 minutes and 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 120 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat between about 15 minutes and about 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 180 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 210 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 270 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 300 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 330 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein the eplivanserin is administered to post-treat at least 360 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM or DOI, wherein eplivanserin is administered to post-treat between about 60 minutes and about 180 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat a subject between at least 15 minutes and 360 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat between at least 30 minutes and 360 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat between at least 60 minutes and 240 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 90 minutes after DOM.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 120 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat between about 15 minutes and about 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 180 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 210 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 270 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 300 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 330 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein the volinanserin is administered to post-treat at least 360 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM or DOI, wherein volinanserin is administered to post-treat between about 60 minutes and about 180 minutes after the administration of the ®-MDMA form.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 15 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat between at least 30 minutes and 360 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat between at least 60 minutes and 240 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 90 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 120 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat between about 15 minutes and about 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 180 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 210 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 270 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 300 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 330 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein the ketanserin is administered to post-treat at least 360 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM or DOI, wherein ketanserin is administered to post-treat between about 60 minutes and about 180 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 15 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 30 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat between at least 60 minutes and 240 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 90 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 120 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat between about 15 minutes and about 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 180 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 210 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 270 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 300 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 330 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein the ritanserin is administered to post-treat at least 360 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM or DOI, wherein ritanserin is administered to post-treat between about 60 minutes and about 180 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 15 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 30 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat between at least 60 minutes and 240 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 90 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 120 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat between about 15 minutes and about 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 180 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 210 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 270 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 300 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 330 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein the pimavanserin is administered to post-treat at least 360 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM or DOI, wherein pimavanserin is administered to post-treat between about 60 minutes and about 180 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 15 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 30 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat between at least 60 minutes and 240 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 90 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 120 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat between about 15 minutes and about 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 180 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 210 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 270 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 300 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 330 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein the nelotanserin is administered to post-treat at least 360 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM or DOI, wherein nelotanserin is administered to post-treat between about 60 minutes and about 180 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 15 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 30 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat between at least 60 minutes and 240 minutes after the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 90 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 120 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat between about 15 minutes and about 150 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 180 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 210 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 240 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 270 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 300 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 330 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein the pruvanserin is administered to post-treat at least 360 minutes after the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM or DOI, wherein pruvanserin is administered to post-treat between about 60 minutes and about 180 minutes after the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 15 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 30 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat between at least 60 minutes and 240 minutes post to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 90 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 120 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat between about 15 minutes and about 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 180 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 210 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 240 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 270 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 300 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 330 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein the flibanserin is administered to post-treat at least 360 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is flibanserin, wherein flibanserin is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 15 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 30 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat between at least 60 minutes and 240 minutes post to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 90 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 120 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat between about 15 minutes and about 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 180 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 210 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 240 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 270 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 300 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 330 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is olanzapine, wherein the olanzapine is administered to post-treat at least 360 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is olanzapine, wherein olanzapine is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 15 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 30 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat between at least 60 minutes and 240 minutes post to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 90 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 120 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat between about 15 minutes and about 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 180 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 210 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 240 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 270 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 300 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 330 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is quetiapine, wherein the quetiapine is administered to post-treat at least 360 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some preferred embodiments, the serotonin receptor modulator is quetiapine, wherein quetiapine is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 15 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 30 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat between at least 60 minutes and 240 minutes post to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 90 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 120 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat between about 15 minutes and about 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 180 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 210 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 240 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 270 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 300 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 330 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is risperidone, wherein the risperidone is administered to post-treat at least 360 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is risperidone, wherein risperidone is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 15 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 30 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat between at least 60 minutes and 240 minutes post to the administration or release of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 90 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 120 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat between about 15 minutes and about 150 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 180 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 210 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 240 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 270 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 300 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some embodiments, the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 330 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the serotonin receptor modulator is buspirone, wherein the buspirone is administered to post-treat at least 360 minutes post to the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein. In some preferred embodiments, the serotonin receptor modulator is buspirone, wherein buspirone is administered to post-treat between about 60 minutes and about 180 minutes post to the administration of the DOM form disclosed herein, including those described in Table Ex3B, Ex5B, or Ex5D, or the DOI HCl form disclosed herein.
  • the combination therapy of the present disclosure comprises administration of a solid form of DOM or DOI, e.g., any of the solid forms of DOM or DOI, as disclosed herein, in combination with a serotonin receptor modulator, as described above.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is eplivanserin, wherein the eplivanserin is administered in about 1 mg to about 40 mg, or about 5 mg to about 10 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is volinanserin, wherein the volinanserin is administered in about 1 mg to about 60 mg, or about 5 mg to about 20 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is ritanserin, wherein the ritanserin is administered in about 1 mg to about 40 mg, or about 2.5 mg to about 10 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator is pimavanserin and the DOM glycolate Form 1 wherein the pimavanserin is administered in about 1 mg to about 60 mg, or about 17 mg to about 34 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is nelotanserin, wherein the nelotanserin is administered in about 1 mg to about 80 mg, or about 40 mg to about 80 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is pruvanserin, wherein the pruvanserin is administered in about 1 mg to about 40 mg, or about 3 mg to about 10 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is flibanserin, wherein the flibanserin is administered in about 10 mg to about 200 mg, or about 80 mg to about 120 mg, or about 100 mg and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is olanzapine, wherein the olanzapine is administered in about 2.5 mg to about 30 mg, or about 5mg or about 10 mg, or about 20 mg or about 25mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is an extended-release of olanzapine such as ZYPREXA RELPREVV, wherein the extended release olanzapine is administered in about 50 mg to about 450 mg, or about 150 mg or about 210 mg, or about 300 mg or about 405 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • olanzapine such as ZYPREXA RELPREVV
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is quetiapine, wherein the quetiapine is administered in about 25 mg to about 800 mg, or about 50 mg to about 100 mg, or about 150mg or about 200mg or about 250mg or about 300mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is an extended-release of quetiapine, wherein the extended-release of quetiapine is administered in about 50 mg to about 300 mg, or about 50mg or about 100 mg or about 200 mg, or about 300 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is risperidone, wherein the risperidone is administered in about 0.5mg to about 20mg or about.5mg, or about 1mg, or about 2mg, or about 3mg or about 4mg or about 5mg or about 7.5mg or about 10mg or about 16mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is an extended-release of risperidone including RISPERDAL CONSTA, wherein the extended-release of risperidone is administered in about 12.5 mg, or about 25 mg, or about 37.5 mg, or about 50 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM glycolate Form 1 is buspirone, wherein the buspirone is administered between about 1 mg to about 100 mg, or about 1 mg or about 2 mg, or about 3 mg, or about 4 mg, or about 5 mg, or about 6 mg, or about 7 mg, or about 7.5 mg, or about 10 mg, or about 15 mg, or about 22.5 mg, or about 30 mg, or about 37.5 mg, or about 45 mg, or about 52.5 mg, or about 60 mg, or about 1 mg to about 10 mg, or about 5 mg to about 10 mg, or about 10 mg to about 15 mg, or about 15 mg to about 30 mg, or about 30 mg to about 60 mg, or about 60 mg to about 80 mg, or about 80 mg to about 100 mg, and the DOM glycolate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is eplivanserin, wherein the eplivanserin is administered in about 1 mg to about 40 mg, or about 5 mg to about 10 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is volinanserin, wherein the volinanserin is administered in about 1 mg to about 60 mg, or about 5 mg to about 20 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is ketanserin, wherein the ketanserin is administered in about 10 mg to about 80 mg, about 30 mg to about 50 mg, or about 40 mg and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is ritanserin, wherein the ritanserin is administered in about 1 mg to about 40 mg, or about 2.5 mg to about 10 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator is pimavanserin and the DOM L- malate Form 1 wherein the pimavanserin is administered in about 1 mg to about 60 mg, or about 17 mg to about 34 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is nelotanserin, wherein the nelotanserin is administered in about 1 mg to about 80 mg, or about 40 mg to about 80 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is pruvanserin, wherein the pruvanserin is administered in about 1 mg to about 40 mg, or about 3 mg to about 10 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is flibanserin, wherein the flibanserin is administered in about 10 mg to about 200 mg, or about 80 mg to about 120 mg, or about 100 mg and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is olanzapine, wherein the olanzapine is administered in about 2.5 mg to about 30 mg, or about 5mg or about 10 mg, or about 20 mg or about 25mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is an extended-release of olanzapine such as ZYPREXA RELPREVV, wherein the extended release olanzapine is administered in about 50 mg to about 450 mg, or about 150 mg or about 210 mg, or about 300 mg or about 405 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • olanzapine such as ZYPREXA RELPREVV
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is quetiapine, wherein the quetiapine is administered in about 25 mg to about 800 mg, or about 50 mg to about 100 mg, or about 150mg or about 200mg or about 250mg or about 300mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is an extended-release of quetiapine, wherein the extended-release of quetiapine is administered in about 50 mg to about 300 mg, or about 50mg or about 100 mg or about 200 mg, or about 300 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is risperidone, wherein the risperidone is administered in about 0.5mg to about 20mg or about.5mg, or about 1mg, or about 2mg, or about 3mg or about 4mg or about 5mg or about 7.5mg or about 10mg or about 16mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is an extended-release of risperidone including RISPERDAL CONSTA, wherein the extended-release of risperidone is administered in about 12.5 mg, or about 25 mg, or about 37.5 mg, or about 50 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator for use with the DOM L-malate Form 1 is buspirone, wherein the buspirone is administered between about 1 mg to about 100 mg, or about 1 mg or about 2 mg, or about 3 mg, or about 4 mg, or about 5 mg, or about 6 mg, or about 7 mg, or about 7.5 mg, or about 10 mg, or about 15 mg, or about 22.5 mg, or about 30 mg, or about 37.5 mg, or about 45 mg, or about 52.5 mg, or about 60 mg, or about 1 mg to about 10 mg, or about 5 mg to about 10 mg, or about 10 mg to about 15 mg, or about 15 mg to about 30 mg, or about 30 mg to about 60 mg, or about 60 mg to about 80 mg, or about 80 mg to about 100 mg, and the DOM L-malate Form 1 is administered between about 0.5 mg and about 15 mg, or about 5 mg.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat between at least 30 minutes prior and 360 minutes prior to the release or administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat between at least 60 minutes prior and 360 minutes prior to the release or administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat between at least 90 minutes and 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 270 minutes prior to DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein the eplivanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is eplivanserin and the psychedelic is DOM glycolate Form 1, wherein eplivanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat a subject between at least 15 minutes and 360 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat between at least 30 minutes and 360 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein the volinanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is volinanserin and the psychedelic is DOM glycolate Form 1, wherein volinanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat between at least 30 minutes and 360 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein the ketanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ketanserin and the psychedelic is DOM glycolate Form 1, wherein ketanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 30 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein the ritanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is ritanserin and the psychedelic is DOM glycolate Form 1, wherein ritanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 30 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein the pimavanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pimavanserin and the psychedelic is DOM glycolate Form 1, wherein pimavanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 30 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein the nelotanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is nelotanserin and the psychedelic is DOM glycolate Form 1, wherein nelotanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 30 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein the pruvanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is pruvanserin and the psychedelic is DOM glycolate Form 1, wherein pruvanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 30 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein the flibanserin is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is flibanserin and the psychedelic is DOM glycolate Form 1, wherein flibanserin is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 30 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat between at least 60 minutes and 240 minutes prior to the administration or release of the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 90 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 120 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat between about 15 minutes and about 150 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 180 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 210 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 240 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 270 minutes prior to the DOM glycolate Form 1. In some embodiments, the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 300 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 330 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein the olanzapine is administered to pretreat at least 360 minutes prior to the DOM glycolate Form 1.
  • the serotonin receptor modulator is olanzapine and the psychedelic is DOM glycolate Form 1, wherein olanzapine is administered to pretreat between about 60 minutes and about 180 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM glycolate Form 1, wherein the risperidone is administered to pretreat at least 15 minutes prior to the administration of the DOM glycolate Form 1.
  • the serotonin receptor modulator is risperidone and the psychedelic is DOM glycolate Form 1, wherein the risperidone is administered to pretreat at least 30 minutes prior to the DOM glycolate Form 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des formes salines et solides du DOM, de la DOI, de la DOB et de la DOC. La forme solide peut être un sel et/ou une forme cristalline du DOM, de la DOI, de la DOB ou de la DOC, tel qu'un polymorphe du DOM, de la DOI, de la DOB ou de la DOC, ou un sel correspondant. L'invention concerne également des procédés de fabrication des formes solides et des procédés d'administration des formes solides. Les formes solides selon l'invention du DOM, de la DOI, de la DOB ou de la DOC sont utiles pour traiter une maladie neurologique et/ou un trouble psychiatrique chez un sujet.
PCT/US2022/081040 2021-12-06 2022-12-06 Formes salines et solides du 1-(2,5-diméthoxy-4-méthylphényl)-2-aminopropane (dom), de la 2,5-diméthoxy-4-iodoamphétamine (doi), de la 2,5-diméthoxy-4-bromoamphétamine (dob) et de la 2,5-diméthoxy-4-chloramphétamine (doc) WO2023107965A1 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202163286415P 2021-12-06 2021-12-06
US202163286419P 2021-12-06 2021-12-06
US202163286405P 2021-12-06 2021-12-06
US202163286491P 2021-12-06 2021-12-06
US63/286,491 2021-12-06
US63/286,405 2021-12-06
US63/286,419 2021-12-06
US63/286,415 2021-12-06
US202263326753P 2022-04-01 2022-04-01
US63/326,753 2022-04-01
US202263367450P 2022-06-30 2022-06-30
US63/367,450 2022-06-30

Publications (1)

Publication Number Publication Date
WO2023107965A1 true WO2023107965A1 (fr) 2023-06-15

Family

ID=86731290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/081040 WO2023107965A1 (fr) 2021-12-06 2022-12-06 Formes salines et solides du 1-(2,5-diméthoxy-4-méthylphényl)-2-aminopropane (dom), de la 2,5-diméthoxy-4-iodoamphétamine (doi), de la 2,5-diméthoxy-4-bromoamphétamine (dob) et de la 2,5-diméthoxy-4-chloramphétamine (doc)

Country Status (1)

Country Link
WO (1) WO2023107965A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210154171A1 (en) * 2015-02-25 2021-05-27 The Regents Of The University Of California 5ht agonists for treating disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210154171A1 (en) * 2015-02-25 2021-05-27 The Regents Of The University Of California 5ht agonists for treating disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Critical Review Report: DOC (4-Chloro-2,5-dimethoxyamfetamine", WORLD HEALTH ORGANIZATION (WHO), 25 October 2019 (2019-10-25), XP093073114, Retrieved from the Internet <URL:https://researchonline.ljmu.ac.uk/id/eprint/11444/1/ECDD42_DOC.pdf> [retrieved on 20230811] *
ANONYMOUS: "DOB hydrochloride", SAFETY DATA SHEET, TOCRIS BIOSCIENCE, XP009547318, Retrieved from the Internet <URL:https://www.tocris.com/products/dob-hydrochloride_2863> [retrieved on 20230207] *
ANONYMOUS: "Dopamine (hydrochloride)", PRODUCT INFORMATION, CAYMAN CHEMICAL, US, US, XP009547319, Retrieved from the Internet <URL:https://www.caymanchem.com/product/21992/dopamine-(hydrochloride)> [retrieved on 20230207] *
COUTTS A N D RONALD T, MALICKY JERRY L: "The Synthesis of Four Possible in vitro Metabolites of the Hallucinogen 1-(2,s-Dimethoxy-4-methylpheny1)-2-aminopropane (DOM)", 1 February 1974 (1974-02-01), pages 395 - 399, XP093073119, Retrieved from the Internet <URL:https://cdnsciencepub.com/doi/pdf/10.1139/v74-063> [retrieved on 20230811], DOI: 10.1139/v74-063 *

Similar Documents

Publication Publication Date Title
US20230192642A1 (en) Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof
JP7241024B2 (ja) （＋）－αジヒドロテトラベナジンコハク酸塩
WO2023086962A1 (fr) Psilocybine et o-acétylpsilocine, leurs sels et formes à l&#39;état solide
US20160347722A1 (en) Novel salts and co-crystals of lesinurad
CZ2016276A3 (cs) Pevné formy volné báze ibrutinibu
US20170166590A1 (en) Crystalline forms of quinolone analogs and their salts
TWI441630B (zh) 曲馬朵（Ｔｒａｍａｄｏｌ）和可舒葆（Ｃｏｘｉｂ）之共結晶物
US11945832B2 (en) Psilocybin and O-acetylpsilocin, salts and solid state forms thereof
WO2023107931A1 (fr) Sel et formes solides d&#39;analogues d&#39;indole et leurs procédés d&#39;utilisation
US9745296B2 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
CN113365614A (zh) 作为神经保护剂的spak激酶抑制剂
US9751847B2 (en) Methods and compositions related to neuroactive thiazoline compounds
US11958821B2 (en) Phenethylamine compounds salts, polymorphic forms and methods of use thereof
US11905295B2 (en) Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders
WO2023107966A1 (fr) Formes salines et solides du diéthylamide de l&#39;acide lysergique (lsd) et analogues
WO2023107965A1 (fr) Formes salines et solides du 1-(2,5-diméthoxy-4-méthylphényl)-2-aminopropane (dom), de la 2,5-diméthoxy-4-iodoamphétamine (doi), de la 2,5-diméthoxy-4-bromoamphétamine (dob) et de la 2,5-diméthoxy-4-chloramphétamine (doc)
WO2023133477A1 (fr) Sels et formes solides d&#39;hémi-glutarate et d&#39;hémi-succinate de 4-hydroxy-n,n-diisopropyltryptamine
KR20200097694A (ko) 통증 및 통증 관련 상태를 치료하기 위한 신규한 알콕시아미노 유도체
US20230150920A1 (en) Salts and solid forms of 4-bromo-2,5-dimethoxyphenethylamine
KR20240056457A (ko) 마크로사이클릭 아졸로피리딘
WO2023147424A1 (fr) Formes salines et solides de n-éthyl-2-(5-fluoro-1h-indol-3-yl)-n-méthyléthan-1-amine
JP2007524620A (ja) 二重機能性化合物及びその使用
US20240034718A1 (en) Salts and solid forms of (r)-1-(5-methoxy-1h-indol-1-yl)-n,n-dimethylpropan-2-amine
US10894768B2 (en) Salt of (R)-(1-methylpyrrolidine-3-yl)methyl(3′-chloro-4′-fluoro-[1,1′-biphenyl]-2-yl)carbamate and crystal form thereof
RU2783865C2 (ru) Фармацевтические композиции

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22905306

Country of ref document: EP

Kind code of ref document: A1